Category Archives: Healthcare & Pharma / 医药医疗

Pharma opening measures under the 2026 action plan

  • The 2026 action plan supports rules for drug segmented manufacturing to facilitate overseas marketing-authorisation holders in cross-border segmented production.
    2026年行动方案支持出台药品分段生产细则,便利境外药品上市许可持有人开展跨境分段生产。
  • Pilot regions for biotechnology and wholly-foreign-owned hospitals will be further expanded.
    生物技术、外商独资医院开放试点区域将进一步扩大。
  • Insurers are encouraged to cover more innovative drugs and devices, and quality innovative products are brought into the retail channel.
    支持保险公司将更多创新药械纳入商业保险,推动优质创新药械进入零售渠道。
  • These are pharma-opening measures under the “stabilizing foreign investment” plan, complementing the general healthcare/pharma market-access brief.
    上述为”固稳促优”方案下的医药开放举措,与通用的医药医疗准入综述互为补充。
  • Eligibility and pilot regions are announced by the drug regulator and pilot-region authorities.
    资格与试点区域由药品监管及试点地区主管部门发布。
  • FIEs should assess segmented-manufacturing and hospital-pilot eligibility against their China strategy.
    外资企业应结合自身中国战略,评估分段生产与人独资医院试点的适用性。

Pharma opening measures under the 2026 action plan | 医药产业开放新措施

Overview

As part of the Action Plan for Stabilizing and Improving Foreign Investment (利用外资固稳促优行动方案), China is advancing a set of pharma and healthcare opening measures (issued 16 June 2026, 商资发〔2026〕97号; effective from 1 July 2026). These refine and extend the market-access path for foreign pharma and medtech companies, sitting alongside the general healthcare/pharma market-access framework.

This article focuses on the pharma-specific openings and is intended as a complement to the broader “Healthcare & pharma market access” brief.

Informational guidance only; exact eligibility and pilot regions are set by the drug regulator (NMPA) and pilot authorities, so verify before acting.

Measures at a glance

Drug segmented manufacturing

  • Study and issue rules for drug segmented manufacturing (药品分段生产实施细则).
  • Facilitate overseas marketing-authorisation holders (MAH) in conducting cross-border segmented manufacturing of biologics and chemical drugs.
  • Allows foreign MAHs to split the manufacturing process across sites/jurisdictions under defined rules, supporting flexible global supply.

Biotech and wholly-foreign-owned hospital pilots

  • Expand pilot regions for biotechnology and wholly-foreign-owned hospitals (外商独资医院).
  • Build an industry collaboration platform to help foreign-invested enterprises’ drugs enter the retail channel.

Insurance coverage and retail access

  • Encourage insurers to include more innovative drugs and devices in commercial insurance coverage.
  • Continuously encourage quality innovative drugs and devices to enter the China market.

How it relates to the broader access brief

  • The general Healthcare & pharma market access article covers NMPA registration, licensing and the baseline path for foreign pharma/medtech entry.
  • This brief covers the 2026 policy increments — segmented manufacturing, expanded pilots, and insurance/retail access — that lower specific frictions for foreign players.
  • Read both: the access brief for the baseline; this brief for the newest openings.

What to do next

  • Foreign MAHs: assess whether segmented manufacturing fits your supply chain and watch for the implementing rules and eligible sites.
  • Medtech/pharma groups: track expanded biotech and wholly-foreign-owned hospital pilot regions for location and eligibility.
  • Market-access teams: engage insurers and retail channels early to plan commercial-insurance and retail access for innovative products.
  • Coordinate with the drug regulator (NMPA) and pilot-region authorities on eligibility and application windows.
  • Combine this brief with the general market-access article when building your China pharma entry plan.

Sources

  • 中华人民共和国中央人民政府(国务院)— 《利用外资固稳促优行动方案》全文:https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局(官方门户)— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号):https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Stabilizing Foreign Investment Action Plan: 15 measures at a glance / 利用外资固稳促优行动方案:15条举措总览

医药产业开放新措施

概述

作为《利用外资固稳促优行动方案》的一部分,中国推进一组医药与医疗开放举措(2026年6月16日印发,商资发〔2026〕97号;自2026年7月1日起落地)。这些举措细化并延伸了外资医药与医疗器械企业的准入路径,与通用的医药医疗准入框架并行。

本文聚焦医药专项开放,旨在作为更广泛”医疗医药准入”综述的补充。

本文仅为信息性指引;具体资格与试点区域由药品监管(NMPA)及试点主管部门规定,行动前请核实。

举措一览

药品分段生产

  • 抓紧研究出台药品分段生产实施细则。
  • 便利境外药品上市许可持有人(MAH)开展生物制品、化学药品的跨境分段生产。
  • 在既定规则下,允许境外 MAH 将生产环节跨场地/辖区拆分,支撑灵活的全球供应。

生物技术与人独资医院试点

  • 扩大生物技术与外商独资医院开放试点区域。
  • 搭建行业协作平台,便利外资企业生产的药品进入零售渠道。

商保覆盖与零售可及

  • 支持保险公司将更多创新药械纳入商业保险保障范围。
  • 持续鼓励优质创新药械进入中国市场。

与通用准入综述的关系

  • 通用的医疗医药准入文章涵盖 NMPA 注册、许可及外资医药/器械来华的基线路径。
  • 本文涵盖2026年政策增量——分段生产、试点扩围、商保与零售可及——即降低外资特定摩擦的举措。
  • 两篇对照阅读:准入综述看基线,本文看最新开放。

下一步建议

  • 境外 MAH:评估分段生产是否契合供应链,关注实施规则与合格场地。
  • 医疗器械/医药集团:跟踪生物技术与人独资医院试点扩围的区域与资格。
  • 市场准入团队:尽早对接保险与零售渠道,规划创新产品的商保与零售可及。
  • 就资格与申报窗口,与药品监管(NMPA)及试点地区主管部门协同。
  • 制定中国医药入华方案时,将本文与通用准入综述结合使用。

来源

  • 中华人民共和国中央人民政府(国务院)— 《利用外资固稳促优行动方案》全文:https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局(官方门户)— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号):https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

相关阅读

  • see also: 医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • see also: 利用外资固稳促优行动方案:15条举措总览 / Stabilizing Foreign Investment Action Plan: 15 measures at a glance

Healthcare & pharma market access (NMPA)

  • Market access hinges on NMPA registration, not foreign approval — an FDA/EMA licence does not register a product in China.
    市场准入关键在于NMPA注册而非境外批准——FDA或EMA许可并不等于在中国注册。
  • Imported drugs and devices need a registered China responsible agent to serve as the domestic Marketing Authorisation Holder stand-in with real lifecycle duties.
    进口药品与器械须有登记的境内责任代理人,作为境内上市许可持有人的代位人,承担真实的全生命周期职责。
  • Clinical trials must follow Chinese GCP with NMPA approval and generally use local sites and Chinese patient populations; overseas data alone may be rejected.
    临床试验须遵循中国GCP并取得NMPA批准,通常须设国内研究中心并纳入中国患者人群;仅境外数据可能被拒。
  • Medical devices are tiered Class I/II/III; overseas manufacturers of Class II/III devices must register their production site with the NMPA.
    医疗器械按风险分一/二/三类;二类、三类境外生产企业须向NMPA登记其生产场地。
  • The NRDL and Volume-Based Procurement (VBP) are the dominant commercial gateways, with VBP tenders cutting prices by often 50%–90%.
    《国家医保药品目录》与集中带量采购(VBP)是主导性商业关口,VBP中标常以50%–90%的降价换取约定采购量。
  • Approved products require Chinese labels and package inserts, and import clearance hinges on the NMPA registration certificate as a key document.
    获批产品须配中文标签与说明书,进口清关以NMPA注册证作为关键单证。

Healthcare & pharma market access (NMPA) | 医疗医药准入(药监局)

Overview

Pharmaceuticals and medical devices are among the most heavily regulated products in China, supervised primarily by the National Medical Products Administration (NMPA). Market access hinges on registration, not merely on foreign approval: a drug or device lawfully sold in the EU or US generally cannot be marketed in China until it has gone through China’s own registration pathway and met Chinese standards.

This article explains the drug and device registration routes, clinical-trial requirements, and the practical steps a foreign pharma or medtech company should plan for. It is informational and must not be treated as regulatory or legal advice; confirm current requirements with the NMPA and qualified PRC counsel.

The NMPA and the marketing-authorisation-holder system

The NMPA (www.nmpa.gov.cn; English: english.nmpa.gov.cn) oversees drugs, medical devices, and cosmetics nationwide, supported by its centres for drug evaluation (CDE), medical-device evaluation (CMDE), and inspection. China operates a Marketing Authorisation Holder (MAH) system: the holder — which may be a domestic entity or, for imported products, the overseas manufacturer represented by a China responsible agent — bears the lifecycle responsibilities for a product. Foreign companies therefore need a registered China agent to act as the domestic responsible party for imported drugs and devices.

The MAH’s responsibilities are not limited to winning approval; they extend across the product’s life — pharmacovigilance and adverse-drug-reaction monitoring, post-market studies and risk-management plans, lot-release and traceability, and recall execution. For imported products, the China responsible agent stands in for the overseas MAH on these duties and can be held directly accountable by the NMPA for quality and safety failures in the China market. This makes agent selection a governance decision, not a paperwork one: the agent must have the regulatory capacity, quality-system interface, and personnel to discharge obligations such as timely adverse-event reporting and recall coordination. A weak agent is a recurring root cause of post-market enforcement actions.

Drug registration pathways

Chemical drugs are classified into five categories (Class 1 innovative, through Classes 2–5 for modified, generic, and imported/domestic equivalents), and biological products follow a parallel framework. A new innovative drug (Class 1) requires full non-clinical and clinical data generated to Chinese Good Clinical Practice (GCP) and Good Laboratory Practice standards. Generic drugs rely on bioequivalence and quality-consistency studies. Imported drugs are registered through the NMPA’s drug-evaluation centre, with dossiers submitted in the required CTD-style format and, for most new drugs, via the marketing-authorisation application after a completed clinical trial approved by the NMPA.

Clinical-trial requirements

Before a human trial in China, the sponsor must obtain NMPA approval (or, for certain listed trials, file a notification) and register the trial in the national drug-trial registration system. Trials must follow Chinese GCP; ethical review by a qualified institutional review board is mandatory, and the use of Chinese patient populations and sites is generally expected so that the data are relevant to the China population. The NMPA has, in recent years, aligned many technical guidelines with ICH standards to ease multinational, multi-regional trials, but local relevance and NMPA acceptance of overseas data still require careful planning.

A related point is the use of the communication channels (Pre-IND and formal communication meetings) with the CDE. The NMPA encourages sponsors to consult the centre at key milestones — before an IND for innovative drugs, on pivotal technical questions, and before the marketing-authorisation application. Meaningful communication materially reduces the risk of later demands for supplementary studies. For overseas-approved drugs that are clinically urgent and not yet marketed in China, conditional approval and priority-review pathways can shorten time-to-market, but they are conditioned on a commitment to complete confirmatory trials. Where overseas data are used for China registration, a racial-sensitivity (ethnic sensitivity) assessment and, where needed, bridging data should be anticipated.

Medical-device registration

Devices are tiered by risk into Class I (low), Class II (medium), and Class III (high). Class I devices are filed with the provincial NMPA office; Class II and III require NMPA or provincial registration (Class III and most Class II are registered with the NMPA/CMDE). Registration demands product technical requirements, type testing at an accredited lab, and a clinical evaluation or trial unless the device is exempt. Quality-system compliance (Good Manufacturing Practice for medical devices) is inspected, and overseas manufacturers of Class II/III devices must register their production site with the NMPA.

Another frequent blind spot in device registration is the choice of clinical-evaluation route. Not every Class II/III device requires a clinical trial: where a product is comparable to an already-marketed device of the same品种, a literature- and data-based “same-species” comparison can support exemption from trials; but novel or high-risk devices with no comparable predicate still need a trial. Companies should settle the clinical-evaluation strategy early — same-species comparison, trial exemption, or full trial — because it dictates the evidence-generation timeline and cost. In addition, the overseas manufacturing site of imported Class II/III devices must be registered with the NMPA, and the clean-room environment and quality system are subject to on-site inspection.

Post-market, labelling, and import considerations

Approved drugs and devices carry Chinese package inserts and labels; foreign-language-only labelling is not sufficient for the China market. Importers and responsible agents must maintain traceability and adverse-event reporting. Imported products enter through customs with the NMPA registration certificate as a key clearance document, and certain products face additional inspection by customs and SAMR. Reimbursement via the National Reimbursement Drug List and Volume-Based Procurement (VBP) are commercial-access factors a market-entry plan should weigh, though they sit outside the registration step itself.

A market-entry plan that stops at registration understates the real access barrier. The National Reimbursement Drug List (NRDL) negotiation and the Volume-Based Procurement (VBP, “集中带量采购”) program are the dominant commercial gateways: inclusion in the NRDL makes a drug reimbursable under basic medical insurance and unlocks hospital demand, while VBP tenders — which now cover many chemical generics, some biosimilars, and high-value devices — award volume in exchange for steep price cuts (often 50%–90%). Winning a VBP tender guarantees large, near-certain volume but at compressed margins, and losing can mean effective exclusion from public hospitals. Foreign companies should model the reimbursement and VBP scenario explicitly rather than treating them as downstream marketing concerns. Separately, data and market-exclusivity protections (e.g. for innovative drugs and paediatric/rare-disease indications) can shape the timing and defensibility of a launch.

Common pitfalls

  • Assuming foreign approval is enough. An FDA or EMA licence does not register a product in China. A separate NMPA pathway, meeting Chinese standards and often Chinese clinical data, is mandatory before any lawful marketing.
  • Relying on overseas trial data alone. Even where NMPA accepts foreign data under ICH-aligned guidance, trials are expected to follow Chinese GCP with local sites and Chinese patient populations; data without local relevance risks rejection or a requirement for bridging studies.
  • Treating the China responsible agent as a formality. The agent is the domestic MAH stand-in with real lifecycle duties — pharmacovigilance, recalls, traceability. A weak agent is a frequent root cause of enforcement.
  • Forgetting the registration certificate at customs. Import clearance hinges on the NMPA registration certificate as a key document; without it the product cannot enter, regardless of foreign readiness.
  • Planning only for registration, not reimbursement. For most drugs and many devices, NRDL inclusion and VBP outcome — not the registration grant — determine commercial viability in the China market.
  • Neglecting the device clinical-evaluation route analysis. Not all devices need trials, but the route choice (same-species comparison, exemption, or trial) sets the evidence cost and launch pace and should be settled at project kick-off.

What to do next

  • Identify the correct classification early (drug class, device Class I/II/III) because it dictates the entire evidence and review path.
  • Appoint a qualified China responsible agent to serve as the domestic party for imported-product registration and post-market duties.
  • Plan clinical trials to Chinese GCP with NMPA approval and local sites; do not assume overseas trial data alone will suffice.
  • Budget for type testing, stability studies, and GMP/site inspection lead times — these, not the fee, are usually the critical path.
  • Prepare Chinese labelling, inserts, and a pharmacovigilance/traceability system before launch.
  • Check reimbursement and VBP exposure as part of the commercial case, separate from registration.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • NMPA — English portal: https://english.nmpa.gov.cn
  • NMPA — government-service portal (drug/device registration and clinical-trial filing): https://zwfw.nmpa.gov.cn
  • NMPA — drug clinical-trial registration system (official portal, see service portal above): https://zwfw.nmpa.gov.cn
  • National Healthcare Security Administration (NHSA) — National Reimbursement Drug List & Volume-Based Procurement: https://www.nhsa.gov.cn/ (official portal)
  • State Administration for Market Regulation (SAMR) — medical-device and related oversight (official portal): https://www.samr.gov.cn/

Related reading

  • see also: Food & beverage market entry & licensing (48-fnb-market-entry-licensing)
  • see also: Financial services & fintech licensing (44-financial-services-fintech-licensing)
  • see also: Import-export licensing & customs clearance (50-import-export-customs-clearance)

医疗医药准入(药监局)

概述

药品与医疗器械是中国监管最严格的产品类别之一,主要由国家药品监督管理局(NMPA)监管。市场准入的关键在于注册,而非仅凭境外批准:在欧盟或美国合法销售的药品或器械,通常须走完中国自身的注册路径并符合中国标准后,方可在华上市。

本文说明药品与器械的注册路径、临床试验要求,以及外资药企与医疗器械公司应规划的实务步骤。本文仅为信息参考,不构成监管或法律意见;请以 NMPA 及合格的中国法律顾问确认最新要求。

药监局与上市许可持有人制度

NMPA(www.nmpa.gov.cn;英文:english.nmpa.gov.cn)统筹全国药品、医疗器械与化妆品监管,下设药品审评中心(CDE)、医疗器械技术审评中心(CMDE)及查验中心。中国实行上市许可持有人(MAH)制度:持有人——可以是境内主体,进口产品则为由境内责任代理人代表的境外生产企业——对产品全生命周期负责。因此,外国公司需要一家已登记的境内代理人,作为进口药品与器械的境内责任主体。

MAH 的职责并不止于取得批准,而是贯穿产品全生命周期——药物警戒与药品不良反应监测、上市后研究与风险管理计划、批签发与可追溯,以及召回执行。对进口产品而言,境内责任代理人就这些职责代行境外 MAH,并可能因中国市场质量与安全问题被 NMPA 直接追责。这使得代理人选择是一项治理决策,而非文书工作:代理人须具备监管能力、质量体系接口与人员,以履行不良反应及时报告与召回协调等义务。薄弱的代理人是上市后执法行动的反复根因。

药品注册路径

化学药品分为五类(1 类创新药,至 2–5 类的改良型、仿制及进口/境内同品种),生物制品遵循平行框架。创新药(1 类)须提供符合中国《药物临床试验质量管理规范》(GCP)与《药物非临床研究质量管理规范》(GLP)的完整非临床与临床数据。仿制药依赖生物等效性与质量和一致性研究。进口药品通过 NMPA 药品审评中心注册,申报资料以 CTD 式格式提交,多数新药须在完成 NMPA 批准的临床试验后,通过上市许可申请注册。

临床试验要求

在中国开展人体试验前,申办方须取得 NMPA 批准(或特定已列明试验须进行备案),并在国家药物临床试验登记与信息公示平台登记。试验须遵循中国 GCP;经资质的伦理委员会审查为强制要求,且通常期望纳入中国患者人群与研究中心,以保证数据对中国人群的相关姓。近年来,NMPA 已将多项技术指南与 ICH 标准接轨,以便利跨国多区域试验,但境外数据的本地相关性与 NMPA 接受度仍需审慎规划。

值得注意的另一点是沟通交流(Pre-IND 与沟通交流会议)机制的利用。NMPA 鼓励申办方在关键节点与 CDE 沟通,尤其是创新药在临床试验申请前、关键技术问题以及上市许可申请前。充分的沟通交流可显著降低后期被要求补充研究的风险。此外,对于在境外已上市、境内未上市的临床急需药品,附条件批准与优先审评审批通道可缩短上市时间,但须以承诺完成确证性试验为前提。境外数据用于中国注册时,还需注意种族敏感性(ethnic sensitivity)评估与必要的桥接数据。

医疗器械注册

器械按风险分为第一类(低)、第二类(中)、第三类(高)。第一类向省级药监部门备案;第二类与第三类须注册(第三类及多数第二类由 NMPA/CMDE 注册)。注册须提交产品技术要求、在资质实验室进行的型检,以及临床评价或临床试验(除非属于豁免目录)。质量体系合规(《医疗器械生产质量管理规范》)须接受检查,第二类/第三类境外生产企业须向 NMPA 登记其生产场地。

器械注册的另一常见盲点是临床评价路径的选择。并非所有二类、三类器械都需临床试验——若产品属同品种已上市器械且能通过同品种比对路径证明安全有效,可免于临床试验;但若无同品种可比或属高风险创新,仍须开展临床试验。企业应尽早做临床评价路径论证,确定是走同品种比对、免于临床,还是临床试验,因为该选择直接决定证据生成的时间与成本。此外,进口二类、三类器械的境外生产场地须完成 NMPA 登记,且洁净生产环境与质量体系须接受现场核查。

上市后、标签与进口考量

已获批药品与器械须配有中文说明书与标签;仅外文标签不足以进入中国市场。进口商与责任代理人须保持可追溯性与不良事件报告。进口产品清关时须以 NMPA 注册证作为关键单证,部分产品还须接受海关与市场监管总局的额外检验。通过《国家医保药品目录》与药品集中带量采购(VBP)获得的报销,是市场准入计划应权衡的商业准入因素,尽管其处于注册步骤之外。

止于注册的准入计划低估了真正的准入壁垒。《国家医保药品目录》(NRDL)谈判与药品集中带量采购(VBP,”带量采购”)是主导性的商业关口:纳入 NRDL 使药品可由基本医疗保险报销,撬动医院需求;而 VBP 带量采购——现覆盖众多化学仿制药、部分生物类似药与高值耗材——以大幅降价(常为 50%–90%)换取约定采购量。中标即锁定大且近乎确定的销量,但利润被压缩;落标则可能被公立医院体系实质排除。外国公司应显式建模报销与 VBP 情景,而非将其视为下游营销问题。此外,数据保护与市场独占期(如创新药及儿科/罕见病适应症的保护)会影响上市的时机与可防御性。

常见误读

  • 以为境外批准即足够。 FDA 或 EMA 许可并不等于在中国注册。在合法上市前,必须走完 NMPA 路径,符合中国标准并常需中国临床数据。
  • 仅凭境外试验数据。 即便 NMPA 在 ICH 接轨指引下接受境外数据,试验仍须遵循中国 GCP 并设国内研究中心、纳入中国患者人群;缺乏本地相关性的数据有被拒或要求桥接研究之险。
  • 把境内责任代理人当文书手续。 代理人是境内 MAH 代位人,承担真实的上市后职责——药物警戒、召回、可追溯。薄弱代理人是执法的常见根因。
  • 在海关忘了注册证。 进口清关以 NMPA 注册证为关键单证;缺少它,产品无法入境,与境外准备程度无关。
  • 只规划注册、不规划报销。 对多数药品与许多器械而言,NRDL 纳入与 VBP 结果——而非注册批件——决定其在中国市场的商业可行性。
  • 忽视临床评价路径论证。 并非所有器械都需临床试验,但路径选择(同品种比对、免于临床或临床试验)决定证据成本与上市节奏,应在立项时即论证。

下一步建议

  • 尽早确定正确分类(药品类别、器械一/二/三类),因其决定整个证据与审评路径。
  • 指定合格的境内责任代理人,作为进口产品注册与上市后职责的境内主体。
  • 按中国 GCP 规划临床试验并取得 NMPA 批准、设立国内研究中心;勿假设仅凭境外试验数据即可。
  • 为型检、稳定性研究及 GMP/场地核查留出时间——通常关键路径在于此而非费用。
  • 上市前准备好中文标签、说明书,以及药物警戒/可追溯体系。
  • 将报销与带量采购敞口作为商业论证的一部分另行评估,与注册分离。

来源

  • 国家药品监督管理局(NMPA)——官方门户:https://www.nmpa.gov.cn
  • NMPA——英文门户:https://english.nmpa.gov.cn
  • NMPA——政务服务门户(药品/器械注册与临床试验登记):https://zwfw.nmpa.gov.cn
  • NMPA——药物临床试验登记与信息公示平台(见政务服务门户):https://zwfw.nmpa.gov.cn
  • 国家医疗保障局(NHSA)——国家医保药品目录与集中带量采购:https://www.nhsa.gov.cn/(官方门户)
  • 国家市场监督管理总局(SAMR)——医疗器械及相关监管(官方门户):https://www.samr.gov.cn/

相关阅读

  • 参见:餐饮食品入华与许可(48-fnb-market-entry-licensing)
  • 参见:金融服务与金融科技牌照(44-financial-services-fintech-licensing)
  • 参见:进出口许可与海关清关(50-import-export-customs-clearances)

Guangdong’s International Medical Services Pilot: Foreign-Patient Growth, Wholly Foreign-Owned Hospitals and What It Means for Healthcare Investors

  • At the 17 August 2026 press conference marking China’s Doctors’ Day, Guangdong’s health commission reported that visits by foreign patients at the 25 pilot international-medical-service hospitals grew 95.6% year on year since the pilot launched in February 2026.
    2026 年 8 月 17 日广东医师节新闻发布会上,省卫健委通报:自 2026 年 2 月国际医疗服务试点启动以来,25 家试点医院外籍人士就医人次同比增长 95.6%。
  • Hong Kong University-Shenzhen Hospital, one of the 25 pilots, has treated patients from 129 countries and regions and served 720,000 foreign patients in the past three years; in 2026 its international medical centre business grew 17.8% year on year from January to July.
    试点之一的香港大学深圳医院已接诊来自 129 个国家和地区的患者,近三年服务境外患者 72 万人次;2026 年 1—7 月其国际医疗中心业务量同比增长 17.8%。
  • Guangdong is accelerating wholly foreign-owned hospital pilots in Guangzhou and Shenzhen: six projects have reached landing intention and three have passed setting approval.
    广东正加快推进广州、深圳外商独资医院试点:已有 6 家项目达成落地意向,其中 3 家已通过设置审批。
  • Internationally oriented services are charged by the patient or their international commercial insurance, outside the basic medical insurance reimbursement scope, following international medical standards, processes and payment models.
    国际医疗服务按国际通行医疗技术标准、服务流程、管理体系和支付模式运营,费用由患者自付或国际商业保险支付,不纳入基本医保报销。
  • Guangzhou launched an international medical tourism service centre in April, issued 12 support measures, and in August released a cross-border insurance settlement platform enabling one-stop no-advance-payment settlement for foreign patients.
    广州 4 月揭牌国际医疗旅游服务中心并发布 12 条支持措施,8 月上线国际医疗跨境支付平台,实现境外患者就医免垫付一站式结算。
  • At national level, the National Health Commission confirmed in August that a second batch of wholly foreign-owned hospital pilot cities is being selected and that high-end specialist medical, rehabilitation and nursing are now in the encouraged catalogue nationwide.
    国家层面,国家卫生健康委 8 月确认正遴选第二批外商独资医院试点城市,并将高端专业医疗、康复、护理纳入全国鼓励范围。

Guangdong’s International Medical Services Pilot: Foreign-Patient Growth, Wholly Foreign-Owned Hospitals and What It Means for Healthcare Investors | 广东国际医疗服务试点:外籍患者增长、外商独资医院与医疗投资者的机会

The pilot and its early results

On 17 August 2026 the Guangdong Provincial Health Commission held its press conference for China’s Doctors’ Day and released the first substantive data on the province’s international medical services pilot. The pilot began in February 2026 when the provincial health commission, the medical security bureau and the drug administration jointly announced the first batch of 25 pilot hospitals, including Guangdong Provincial People’s Hospital, the First Affiliated Hospital of Sun Yat-sen University, Hong Kong University-Shenzhen Hospital and Zhuhai People’s Hospital. Since the launch, visits by foreign patients to the international and special-need medical departments of the 25 hospitals grew 95.6% year on year. The business model is explicitly international: services follow internationally accepted medical technical standards, service processes, management systems and payment models, targeting residents of Hong Kong, Macao and Taiwan, foreign nationals and overseas Chinese who pay out of pocket or through international commercial insurance, outside the scope of basic medical insurance reimbursement.

The scale and shape of demand

The pilot data show a large and growing cross-border patient pool. HKU-Shenzhen Hospital has treated patients from 129 countries and regions and served 720,000 foreign patients over three years; since joining the pilot, its international medical centre business grew 17.8% year on year in January–July 2026, with outpatient and check-up volumes up 16.4% and discharges up 33.5%, and Hong Kong patients accounting for 30% of outpatient and 20% of inpatient volumes. Guangdong’s position in the Greater Bay Area gives it a unique catchment: cross-border commuting workers, Hong Kong and Macao residents, and a deep stock of manufacturing-linked expatriate communities across the Pearl River Delta. For healthcare investors, the demand signal is that international-standard care priced outside the public insurance pool is a viable commercial segment in Guangdong, not a marginal one.

Wholly foreign-owned hospital acceleration

The most important development for foreign investors is the acceleration of wholly foreign-owned hospital pilots in Guangzhou and Shenzhen. Guangdong’s health commission reported that six projects have reached landing intention and three have passed setting approval. This follows the national framework: the September 2024 pilot notice and the November 2024 Plan for Expanding the Wholly Foreign-Owned Hospital Pilot, which set the conditions, requirements and procedures, and under which four wholly foreign-owned hospitals have already landed in Tianjin, Shanghai, Boao and Fuzhou. The National Health Commission confirmed in August 2026 that it is selecting a second batch of pilot cities, expanding from “point pilots” to regional rollout, and that the encouraged catalogue for foreign investment (2025 edition) now includes high-end specialist medical, rehabilitation and nursing nationwide. For a foreign hospital operator, Guangdong’s Guangzhou and Shenzhen are the most active frontier.

The stem-cell and gene-technology opening

A further dimension of the medical opening is technological. The National Health Commission confirmed in August 2026 that, in the Beijing, Shanghai and Guangdong free trade zones and the Hainan Free Trade Port, foreign-invested enterprises are permitted to conduct R&D and application of human stem-cell and gene-diagnosis and therapy technologies for the purpose of product registration and marketing, with approved products usable nationwide. For foreign biotech and cell-therapy companies, this converts the FTZ and Hainan pilots into a route to develop, register and market advanced therapies in China — subject to the full regulatory chain of human genetic resource administration, clinical trials (including international multicentre trials), drug registration and production licensing and ethics review. This is a significant expansion of the addressable market for foreign cell and gene therapy developers.

Guangzhou’s ecosystem building

Beyond the hospital pilots, Guangzhou is building the surrounding service ecosystem. In April 2026 the Guangzhou International Medical Tourism Service Centre was inaugurated, integrating the resources of 17 pilot hospitals in the city with the cultural-tourism and exhibition group; on the same day the city health commission issued 12 support measures for international medical services covering benchmark projects, resource clustering, talent attraction, payment convenience and TCM internationalisation. In August 2026, at the international medical innovation exchange and the Guangzhou Medical and Health Industry Expo, the Guangzhou Hospital Association’s International Medical Services Management Branch was established — the first industry management platform of its kind in the city — and a cross-border medical payment platform was released, enabling one-stop settlement for foreign patients without out-of-pocket advance payments through bank and insurer coordination. The city reports that foreign patients now come from 133 countries and regions, up from 90-plus before the tourism service centre opened, and that foreign patient volumes grew over 30% in the first half of the year to 260,000.

Practical guidance for healthcare investors

First, assess the pilot structure: wholly foreign-owned hospital entry requires setting approval, hospital licensing and alignment with the 2024 pilot conditions; the accelerated pace in Guangzhou and Shenzhen means the window is now. Second, understand the payment model: international services sit outside basic insurance, so pricing, insurance networks and cross-border settlement platforms are the commercial core. Third, for cell and gene therapies, evaluate the FTZ route in Guangdong (or Beijing, Shanghai, Hainan) for R&D and registration, and map the full regulatory chain early. Fourth, consider partnership with the 25 pilot hospitals — many are state-owned and are building international departments and tourism-service links, which offers a lighter entry than greenfield ownership. Fifth, monitor the second batch of pilot cities nationally and the encouraged-catalogue benefits (import duty, land, tax) that attach to encouraged categories. The Guangdong data prove the demand; the policy framework proves the intent; the remaining question for investors is execution speed and structure.

Outlook

Guangdong’s international medical pilot is the clearest demonstration yet that China’s healthcare opening has moved from policy text to commercial reality. Foreign-patient growth of nearly double in six months, wholly foreign-owned hospitals passing setting approval in Guangzhou and Shenzhen, a cross-border payment platform in operation and a provincial data trail — each of these would have been difficult to imagine two years ago. For foreign healthcare and biotech investors, the region is now a serious candidate for first entry into China’s mainstream private healthcare market.

Sources


广东国际医疗服务试点:外籍患者增长、外商独资医院与医疗投资者的机会

试点与早期成果

2026 年 8 月 17 日,广东省卫生健康委员会举行第九个中国医师节新闻发布会,公布国际医疗服务试点首批实质性数据。试点始于 2026 年 2 月,省卫健委、省医保局、省药监局联合公布首批 25 家试点医院名单,包括广东省人民医院、中山大学附属第一医院、香港大学深圳医院、珠海市人民医院等。启动以来,25 家医院国际医疗和特需医疗板块外籍人士就医人次同比增长 95.6%。业务模式明确国际化:按国际通行的医疗技术标准、服务流程、管理体系和支付方式运营,面向港澳台居民、外籍人士、海外华人等自费或持有国际商业保险的人群,费用不纳入基本医保报销。

需求的规模与形态

试点数据显示庞大且增长的跨境患者池。港大深圳医院已接诊来自 129 个国家和地区的患者,近三年服务境外患者 72 万人次;纳入试点后,2026 年 1—7 月国际医疗中心业务量同比增长 17.8%,门急诊和体检业务量增长 16.4%,出院量增长 33.5%,香港患者门急诊占比 30%、住院占比 20%。广东在大湾区的位置带来独特客源:跨境通勤人群、港澳居民、以及珠三角制造业沉淀的庞大外派社区。对医疗投资者,需求信号是:定价在公共医保池之外的国际标准医疗服务,在广东是可行的商业细分,而非边缘。

外商独资医院提速

对外国投资者最重要的进展是广州、深圳外商独资医院试点的加快。广东省卫健委通报,已有 6 家项目达成落地意向,其中 3 家已通过设置审批。这延续全国框架:2024 年 9 月开放试点通知与 2024 年 11 月《独资医院领域扩大开放试点工作方案》设定条件、要求与程序,首批 4 家外商独资医院已在天津、上海、博鳌、福州落地。国家卫生健康委 2026 年 8 月确认正遴选第二批试点城市,从”点状试点”向”区域推广”拓展;《鼓励外商投资产业目录(2025 年版)》已把高端专业医疗、康复、护理纳入全国鼓励范围。对外国医院运营者,广东的广州、深圳是最活跃的前沿。

干细胞与基因技术的开放

医疗开放的另一个维度是技术层面。国家卫生健康委 2026 年 8 月确认,在北京、上海、广东自贸试验区和海南自由贸易港,允许外商投资企业从事人体干细胞、基因诊断与治疗技术开发和应用,以用于产品注册上市和生产,经注册上市和批准生产的产品可在全国使用。对外国生物技术与细胞治疗企业,这使自贸试验区与海南试点转化为在中国开发、注册与上市先进疗法的路径——前提是走完整监管链:人类遗传资源管理、临床试验(含国际多中心临床试验)、药品注册上市、生产许可与伦理审查。这是外国细胞与基因治疗开发商可及市场的重大扩展。

广州的生态建设

在医院试点之外,广州正在建设周边服务生态。2026 年 4 月,广州国际医疗旅游服务中心揭牌,联动全市 17 家试点医院资源与文旅会展集团;同日市卫健委发布 12 条支持国际医疗服务创新举措,覆盖标杆打造、资源集聚、人才引育、支付便利与中医药国际化。2026 年 8 月,在国际医疗创新发展交流会暨广州医疗与健康产业博览会上,广州市医院协会国际医疗服务管理分会成立——全市首个专注国际医疗服务的行业管理平台——并发布国际医疗跨境支付平台,经政府、银行与保险机构协调实现境外患者就医免垫付一站式结算。广州报告境外患者来源地已从服务中心成立前的 90 多个国家和地区升至 133 个,上半年境外患者增长超 30%、达 26 万人次。

医疗投资者实操指引

其一,评估试点结构:外商独资医院进入须通过设置审批、医疗机构执业登记并符合 2024 年试点条件;广州、深圳提速意味着窗口期就在当下。其二,理解支付模式:国际服务在基本医保之外,定价、保险网络与跨境结算平台是商业核心。其三,细胞与基因疗法:评估广东(或北京、上海、海南)自贸试验区研发与注册路径,尽早梳理完整监管链。其四,考虑与 25 家试点医院合作——多数为公立,正在建设国际部与旅游服务链接,比绿地自有更轻的进入方式。其五,关注全国第二批试点城市与鼓励目录红利(进口关税、用地、税收)。广东数据证明了需求,政策框架证明了意图,留给投资者的问题是执行速度与结构。

展望

广东国际医疗试点是中国医疗开放从政策文本走向商业现实迄今最清晰的例证。六个月内外籍患者近翻倍增长、广州深圳外商独资医院通过设置审批、跨境支付平台投入运营、省级数据链条成形——每一项在两年前都难以想象。对外国医疗与生物科技投资者,该区域现已成为进入中国主流私立医疗市场的严肃首选地。

Sources

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs

  • On 15 May 2026 the revised Implementation Regulations of the Drug Administration Law took effect, with Article 32 expressly allowing segmented (split-site) production of qualifying innovative drugs under a unified quality-assurance system.
    2026年5月15日,新修订的《药品管理法实施条例》施行,其中第三十二条明确允许符合条件的创新药在统一质量保证体系下分段委托生产。
  • The State Drug Administration has separately worked on biological-product segmented production; the 2026 Action Plan to Stabilise and Optimise Foreign Investment now calls for detailed rules for cross-border segmented production of both biologicals and chemical drugs.
    国家药监局已就生物制品分段生产单独发文推进;2026年《利用外资固稳促优行动方案》进一步提出研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • Segmented production applies to innovative drugs with special production-process or facility requirements, clinically urgent drugs, and drugs needed for public-health emergencies, as designated by the State Council.
    分段生产适用于生产工艺、设施设备有特殊要求的创新药,临床急需的药品,以及突发公共卫生事件急需或储备需要的药品等国务院规定情形。
  • The marketing authorisation holder (MAH) remains the single, final quality-responsible party and must build a unified quality-assurance system spanning all production sites.
    药品上市许可持有人(MAH)仍是唯一、最终的质量责任主体,必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系。
  • For foreign MAHs, the combination of segmented production and the FIE action plan opens a path to structure cross-border biologics and chemical manufacturing while keeping Chinese regulatory responsibility centralised.
    对外资MAH而言,分段生产与稳外资行动方案的组合,为跨境生物制品与化学药品生产布局开辟了路径,同时保持中国监管责任集中化。
  • Commercial insurers are also being encouraged to cover more innovative drugs and devices, and foreign-made drugs gain smoother entry into retail channels.
    政策同时鼓励保险公司将更多创新药械纳入商业保险保障范围,并便利外资企业生产的药品进入药品零售渠道。

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs | 中国药品分段生产:外资上市许可持有人的制造新选项

Why this matters now

Pharmaceutical manufacturing has traditionally meant one site, one product, one end-to-end process. China’s 2026 regulatory wave is deliberately unpicking that assumption. On 15 May 2026, the revised Implementation Regulations of the Drug Administration Law took effect, and Article 32 explicitly permits the segmented production of qualifying innovative drugs — where manufacturing steps run at different sites and potentially through different companies — as long as the marketing authorisation holder maintains a unified quality-assurance system. The move is paired with an explicit signal to foreign investors: the June 2026 Action Plan to Stabilise and Optimise Foreign Investment (issued by MOFCOM, NDRC and MOF) commits to detailed rules for cross-border segmented production of biological products and chemical drugs, building on the earlier biological-product segmented-production pilot. For a global pharma company with an approved innovative molecule, this changes how production for the Chinese market can be structured.

What segmented production covers

Article 32 of the revised Implementation Regulations permits segmented production for three categories: innovative drugs whose production process, equipment or facilities have special requirements; clinically urgent drugs requested by relevant State Council departments; and drugs needed for emergency response or stockpiling. The MAH may commission qualified production enterprises to handle separate production steps. Critically, the law does not decentralise responsibility: the MAH must establish a unified quality-assurance system covering the entire production process and all production sites, and remains the single final responsible party for product quality. The State Drug Administration’s inspection guidance for biological-product segmented production further requires the MAH to align quality-management systems across segment producers, apply quality-risk management to contamination and cross-contamination risks, and ensure the quality authorisation holder can base final release decisions on a full review of data from all segments.

The foreign-investment angle

The FIE Action Plan published in June 2026 explicitly says the authorities will move quickly to issue implementation rules for segmented production, to facilitate overseas drug marketing authorisation holders in carrying out cross-border segmented production of biologicals and chemical drugs. This is the first time the policy explicitly opens the door to cross-border arrangements — a Chinese plant handling one production step, an overseas site another. For foreign MAHs, the practical attraction is manufacturing flexibility: an API or biologic intermediate can be produced at the site with the best economics and IP-protection profile, with final formulation and packaging in China, while quality oversight remains anchored in one unified system. The same plan adds supporting measures: expanding the pilot scope for biotechnology and wholly foreign-owned hospitals, encouraging commercial insurers to cover more innovative drugs and devices, and easing foreign-made drugs into retail pharmacy channels.

Practical steps for foreign MAHs

  1. Map your portfolio. Identify molecules that qualify for segmented production — innovative drugs with special process or facility needs, clinically urgent products, or emergency/stockpile candidates.
  2. Decide the China anchor. Choose which production step will be performed in China and by which qualified manufacturer, and where the MAH quality-authorisation function will sit.
  3. Design the unified quality system. Draft the single quality-assurance framework covering all sites and segments, including technology transfer, change control, deviation handling and CAPA procedures.
  4. Engage the SDA early. Because implementation rules for chemical cross-border segmented production are still being drafted, use pre-submission consultation channels to align on expectations before committing investment.
  5. Review supply-chain economics. Model the tax, customs and logistics treatment of intermediates moving across borders, including bonded and duty-free options where available.
  6. Coordinate with insurance and retail access. Plan for how the product will reach patients — commercial insurance coverage and retail channel entry both affect market-access planning.

Risks and compliance notes

Segmented production is a permission, not a relaxation. The MAH’s single-responsibility rule means a failure at any segment is ultimately the MAH’s failure; contract manufacturers’ systems must be auditable and aligned. Foreign MAHs should also track the still-evolving implementation rules for chemical cross-border segmented production — until they issue, cross-border arrangements for small-molecule drugs should be structured conservatively. IP protection of process know-how across borders, GMP consistency between sites, and batch-release responsibilities all need contractual precision. Finally, the SDA’s on-site inspection and post-market supervision powers are unchanged, so documentation and traceability must satisfy the same standards as single-site production.


中国药品分段生产:外资上市许可持有人的制造新选项

为什么当下重要

药品生产传统上意味着”一个场地、一个产品、一条端到端流程”。中国2026年的监管浪潮正有意拆解这一假设。2026年5月15日,新修订的《药品管理法实施条例》施行,第三十二条明确允许符合条件的创新药分段生产——即制造环节在不同场地、甚至经由不同公司运行——只要上市许可持有人维护统一质量保证体系。该举措与对外资投资者的明确信号相配合:2026年6月商务部、国家发展改革委、财政部发布的《利用外资固稳促优行动方案》承诺研究出台生物制品与化学药品跨境分段生产实施细则,在早期生物制品分段生产试点基础上推进。对拥有获批创新分子的全球制药企业而言,这改变了中国市场的生产布局方式。

分段生产覆盖哪些情形

修订后《实施条例》第三十二条允许三类药品分段生产:生产工艺、设施设备有特殊要求的创新药;国务院有关部门提出的临床急需药品;以及应对突发公共卫生事件急需或储备需要的药品。MAH可以委托符合条件的生产企业承担不同生产步骤。关键在于,法律并未分散责任:MAH必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系,并作为产品质量唯一且最终的责任主体。国家药监局生物制品分段生产现场检查指南进一步要求MAH使各分段生产企业的质量管理体系有效衔接与统一,运用质量风险管理方法识别控制污染、交叉污染及差错风险,并确保质量受权人能基于对各分段数据的全面审核作出最终放行决定。

外资维度

2026年6月发布的稳外资行动方案明确提出,抓紧研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。这是政策首次明确为跨境安排敞开大门——中国工厂承担一个生产步骤,海外场地承担另一个。对外资MAH而言,实际吸引力在于制造灵活性:原料药或生物制品中间体可在经济性与知识产权保护最优的场地生产,最终制剂与包装放在中国,而质量监督仍锚定于一个统一体系。同一方案还附带了配套措施:扩大生物技术、外商独资医院开放试点区域范围,支持保险公司将更多创新药械纳入商业保险,并便利外资企业生产的药品进入零售药店渠道。

外资MAH的操作步骤

  1. 梳理产品组合。 识别符合分段生产条件的分子——生产工艺或设施有特殊要求的创新药、临床急需产品或应急/储备候选品。
  2. 确定中国锚点。 选择哪个生产步骤在中国、由哪家合格生产商执行,以及MAH质量受权职能设在何处。
  3. 设计统一质量体系。 起草覆盖全部场地与分段的单一质量保证框架,包括技术转移、变更控制、偏差处理与CAPA程序。
  4. 尽早与国家药监局沟通。 由于化学药品跨境分段生产实施细则仍在起草中,在投入投资前应利用预沟通渠道对齐预期。
  5. 审查供应链经济性。 建模中间体跨境流动的税收、海关与物流处理,在可行时考虑保税与免税选项。
  6. 协同保险与零售准入。 规划产品如何触达患者——商业保险覆盖与零售渠道进入都影响市场准入规划。

风险与合规提示

分段生产是许可,不是放松。MAH单一责任规则意味着任何分段的失败最终都是MAH的失败;合同生产商的体系必须可审计、可对齐。外资MAH还应跟踪仍在制定的化学药品跨境分段生产实施细则——在细则出台前,小分子药物跨境安排应保守设计。跨境工艺know-how的知识产权保护、场地间GMP一致性、批次放行责任都需要合同上的精确性。最后,药监局现场检查与上市后监管权限不变,因此文档与可追溯性必须满足与单一场地生产相同的标准。

Sources

  • 商务部 国家发展改革委 财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号)——第三条”支持外资参与医药等产业高质量发展”(研究出台药品分段生产实施细则、便利境外MAH跨境分段生产):https://sxdofcom.shaanxi.gov.cn/fdi/yhzc/40265.jhtml
  • 商务部副部长凌激出席国新办发布会介绍利用外资固稳促优有关政策措施(王亚回应医药开放措施,生物制品分段生产试点、化学药品跨境分段生产细则):https://swj.wulanchabu.gov.cn/zxft/1994919.html
  • 中国医药创新促进会《药品管理法实施条例大家谈 在鼓励创新与严守底线间找到平衡》(第三十二条分段生产、MAH统一质量保证体系解读):https://www.phirda.com/artilce_43447.html
  • 山西省民营经济发展局官网《外资企业可重点关注哪些扩大准入领域?》(2026-08-10,摘自商资发〔2026〕97号:药品分段生产、生物技术和外商独资医院领域扩大开放):https://myj.shanxi.gov.cn/ztzl/bwbd/lywzgw/202608/t20260810_10196322.shtml

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening

  • The “Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector” (NHC, MOFCOM et al., Guowei Yizhengfa [2024] No. 36) permits wholly foreign-owned hospitals in nine provincial regions.
    国家卫生健康委、商务部等四部门《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)允许在9个省市设立外商独资医院。
  • The pilot covers Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan, explicitly excluding TCM institutions and the acquisition of public hospitals.
    试点范围涵盖北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛,明确排除中医类机构与并购公立医院。
  • Eligible hospitals are general, specialised or rehabilitation hospitals at tertiary level; blood-disease, psychiatric, infectious-disease and TCM hospitals are barred, and haematology is excluded from the practice scope.
    符合条件的医院类别为综合医院、专科医院、康复医院且级别为三级;禁止设立血液病、精神病、传染病、中医医院,且诊疗科目不得登记血液内科。
  • Foreign and HK/Macao/Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must make up at least 50% of both management and professional staff.
    可按规定聘用外国及港澳台医师短期执业,但全院管理与卫生专业技术人员的中方(内地)人员占比均不得少于50%。
  • Approval sits with provincial health authorities (setting approval plus a five-year practice licence), with information systems connected to local regulatory platforms and data servers located in China.
    设置审批与执业登记由省级卫生健康行政部门核发(执业许可证有效期5年),信息管理系统须接入属地监管平台,服务器位于境内。
  • The plan folds into a broader “orderly expansion of opening in the medical sector” and offers foreign investors a greenfield route distinct from the previous Sino-foreign joint-venture hospital model.
    该方案属于”医疗领域有序扩大开放”整体部署,为外资提供区别于以往中外合资合作医院模式的新设独资路径。

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening | 外资独资医院试点与社会办医扩大开放

Why this matters now

For foreign healthcare groups, China’s hospital market has long been accessible only through joint ventures or minority stakes under the Sino-foreign cooperative medical-institution framework. The late-2024 pilot to permit wholly foreign-owned hospitals changes that calculus: it creates a greenfield route for international operators to build and control a hospital on the mainland, bringing management models, clinical pathways and technology that complement the public system. The pilot is deliberately scoped — geographic, institutional and clinical guardrails are explicit — so the opportunity is real but bounded.

Market context: demand and the foreign-model case

The nine pilot regions are not arbitrary. They combine high openness, dense clusters of foreign enterprises and expatriates, and mature experience regulating foreign-funded medical institutions — exactly the conditions where demand for international-standard care is strongest. Foreign-invested hospitals are positioned to complement, not compete with, the public system: they target high-end and specialised demand, expatriate and cross-border patients, and technology- and service-model transfer that raises local standards. For provincial authorities, the pilot is also a service-environment upgrade that helps retain foreign talent and investment. The 50% mainland-personnel floor and the data-localisation duty, however, mean a foreign operator must build genuine local capability rather than merely import a brand. Realistic entrants therefore pair an international clinical franchise with a credible本地 workforce, IT and quality-system plan from day one.

The pilot framework

Issued by the National Health Commission, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration (Guowei Yizhengfa [2024] No. 36, 1 November 2024), the plan authorises wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan. TCM-category institutions are excluded, and acquiring public hospitals is not permitted. The nine regions were chosen for high openness, concentrated foreign enterprises and expatriates, and mature experience in regulating foreign-funded medical institutions.

Eligibility and operating conditions

The investor must be a legal person able to bear civil liability independently, with direct or indirect experience in healthcare investment and management, and must demonstrate international-leading management, models and equipment that supplement local supply. The hospital itself:

  • may be for-profit or non-profit;
  • must be a general, specialised or rehabilitation hospital at tertiary level — psychiatric, infectious-disease, blood-disease and TCM hospitals are prohibited;
  • may not register haematology as a practice department; and
  • may not conduct high-ethical-risk activities such as organ transplantation, assisted reproductive technology, prenatal screening/diagnosis, psychiatric inpatient care, or experimental cellular tumour therapies.

Foreign, HK/Macao and Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must constitute at least 50% of both the management and the professional workforce. Information systems must connect to the local medical-service supervision platform, and electronic medical records and device data must be stored on servers located in China. Hospitals meeting medical-insurance rules may apply to join the designated insurance network and are encouraged to connect with domestic and international commercial health insurance.

Approval and supervision

Setting approval and practice registration are handled at the prefecture level for initial review and then by the provincial health authority, which issues the certificate of hospital establishment and the practice licence (valid five years, renewable). The licence is brought into the medical-quality safety-management system; hospitals are encouraged to participate in accreditation, and provincial and prefecture authorities conduct ongoing monitoring and coordinated supervision. Importantly, where the pilot conflicts with prior rules, the pilot plan prevails — giving it operative priority during the trial period.

Complementary openings across the medical sector

The hospital pilot is one move in a broader, sequenced opening of the healthcare and pharmaceutical sector. Around the same period, China removed or relaxed restrictions on foreign investment in several medical and aged-care sub-sectors, and the negative list has progressively shed items that previously capped foreign-invested enterprises in healthcare. Innovative-drug and medical-device access pathways have also been streamlined, and Greater Bay Area “medtech connexion” arrangements ease cross-boundary use of approved drugs and devices for residents. Read together, these signal a directional intent to let foreign capital and expertise enter where domestic supply is constrained or where international standards add value. Foreign groups should therefore map the hospital route against this wider roadmap — a hospital licence may pair naturally with device, pharma or senior-care ventures that share the same patient and regulatory ecosystem.

Practical steps for foreign investors

  1. Select a pilot region and confirm the hospital typology (general/specialised/rehabilitation, tertiary) against the exclusions.
  2. Prepare the investment and operating case showing international management, technology and capacity complementarity.
  3. Build the mainland workforce plan that satisfies the 50% Chinese personnel threshold across both management and clinical staff.
  4. Architect the IT and data posture — local servers, platform connectivity, and a data-governance stance consistent with China’s data-security and personal-information rules.
  5. Engage the provincial health authority early for the two-step approval, and plan for the five-year licence cycle and renewal.

Related reading

The hospital pilot sits inside a wider opening of the medical and pharmaceutical sector — from innovative-drug and device access to the negative list’s removal of certain restricted sub-sectors. Foreign groups should read the hospital route together with the broader healthcare-market-access roadmap.


外资独资医院试点与社会办医扩大开放

为何当下值得关注

对境外医疗集团而言,中国医院市场长期以来只能通过合资或少数股权路径进入(即中外合资合作医疗机构框架)。2024年底推出的”允许设立外商独资医院”试点改变了这一格局:它为国际运营方提供了一条在内地自主建设并控股医院的绿地路径,用以引入与公立医院体系互补的管理模式、临床路径与技术。该试点边界清晰——地理、机构与临床层面均设有明确护栏——因此机遇真实但有限定。

市场背景:需求与外资模式的逻辑

9个试点地区并非随意选取。它们兼具对外开放程度高、外资企业与外籍人员密集、监管外资医疗机构经验成熟等特征——恰恰是国际水准医疗需求最旺盛的条件。外商独资医院定位于与公立医院体系互补而非竞争:瞄准高端与专科需求、外籍及跨境患者,并以技术与管理模式转移提升本地标准。对省级政府而言,试点也是留住外资人才与投资的营商环境升级。但中方人员不少于50%与数据本地化义务,意味着外资运营方须建设真实的本地能力,而非仅引入品牌。务实的进入者因此从第一天起就将国际临床品牌与可信的本地人才、IT与质量体系计划相配对。

试点框架

由国家卫生健康委、商务部、国家中医药局、国家疾控局联合印发(国卫医政发〔2024〕36号,2024年11月1日),方案授权在北京、天津、上海、南京、苏州、福州、广州、深圳以及海南全岛设立外商独资医院。明确排除中医类机构,且不允许并购公立医院。选取这9个省市,是因为其对外开放程度高、外资企业与外籍人员集中,且积累了丰富的外资医疗机构管理经验。

资质与运营条件

境外投资者须为能够独立承担民事责任的法人,具有直接或间接医疗卫生投资与管理经验,并能提供国际先进的管理理念、模式与服务,以及国际领先的技术与设备,以补充或改善当地医疗服务能力。医院本身须满足:

  • 经营性质可为营利性或非营利性;
  • 类别为综合医院、专科医院、康复医院且级别为三级——禁止设立精神病、传染病、血液病、中医医院;
  • 诊疗科目不得登记血液内科;
  • 不得开展人体器官移植、人类辅助生殖、产前筛查与诊断、精神科住院治疗、肿瘤细胞治疗新技术试验性治疗等伦理风险较高的诊疗活动。

可按规定聘用外国及港澳台医师短期执业,但中方(内地)人员须占全院管理与卫生专业技术人员的均不少于50%。信息管理系统须接入属地医疗服务监管平台,电子病历与医用设备等信息存储服务器须位于中国境内。符合医保规定的医院可按程序申请纳入医保定点,并鼓励对接国内外商业健康保险。

审批与监管

设置审批与执业登记由地市级卫生健康行政部门初审、省级卫生健康行政部门核发设置医疗机构批准书与医疗机构执业许可证(有效期5年,期满可续)。医院纳入医疗质量安全管理范畴,鼓励参加医院评审评价,省级与地市级部门开展动态监测与协同监管。值得注意的是,原有规定与本试点方案不符的,以本方案为准——在试点期内具有操作优先性。

医疗行业更广维度的配套开放

医院试点只是医疗与医药行业有序、分批扩大开放中的一步。同一时期,中国在多个医疗与养老子行业取消或放宽了外资准入限制,负面清单也逐步删除了此前约束医疗卫生领域外商投资企业的条目。创新药与医疗器械准入路径同步简化,粤港澳大湾区”港澳药械通”等安排也便利了居民跨境使用已获批药品与器械。综合来看,这些举措释放出允许外资与专长进入供给受限或国际标准的确能增值领域的导向性意图。外资集团因此应将医院路径置于更宏观的路线图中研判——一张医院牌照可能天然与共享同一患者与监管生态的器械、药品或养老业务协同。

外资投资者实务步骤

  1. 选定试点地区,并对照排除项确认医院类型(综合/专科/康复,三级)。
  2. 准备投资与运营方案,论证国际管理、技术与能力互补性。
  3. 构建内地人才计划,满足管理与临床中方人员均不少于50%的要求。
  4. 设计IT与数据架构——境内服务器、平台对接,以及与数据安全、个人信息保护规则一致的数据治理立场。
  5. 尽早对接省级卫生健康行政部门完成两步审批,并规划5年证照周期与续期。

延伸阅读

医院试点位于医疗与医药行业更广开放版图之中——从创新药与医疗器械准入,到负面清单取消若干受限子行业。外资集团应将医院路径与更宏观的医疗服务市场准入路线图一并研读。

Sources

  • 国家卫生健康委、商务部、国家中医药局、国家疾控局:《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)— https://www.gov.cn/zhengce/zhengceku/202411/content_6990279.htm

Foreign-invested hospitals: the 2026 liberalisation and where they can land

  • Wholly-foreign-owned hospitals are piloted in nine regions — Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island — under the Nov-2024 pilot plan; outside those areas foreign-invested hospitals remain equity or cooperative joint ventures.
    外商独资医院在九地试点——北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛——依 2024 年 11 月试点方案;试点外外资办医仍以合资/合作形式为主。
  • China’s first wholly-foreign-owned tertiary general hospital — Tianjin Pengruili Hospital — opened on 26 February 2025 with about ¥1 billion invested and 500 beds, after Tianjin issued the first such licence on 16 December 2024.
    中国首家外商独资三级综合医院天津鹏瑞利医院于 2025 年 2 月 26 日开诊,投资约 10 亿元、设 500 张床位;天津于 2024 年 12 月 16 日颁发首张该类执业许可证。
  • The 2026 action plan commits to further expanding the biotech and wholly-foreign-owned-hospital pilot regions after evaluating the initial rollout, signalling that more cities will be added.
    2026 年行动方案承诺在评估初期落地情况后进一步扩大生物技术及外商独资医院试点区域,预示更多城市将加入。
  • The Jan-2026 “nine-city services-opening” comprehensive pilot assigned 159 tasks (103 common plus 3 added) spanning medical-senior-care opening, telecom and finance — extending the policy floor beyond the nine hospital-pilot regions.
    2026 年 1 月”9 城市服务业扩大开放”综合试点部署 159 项任务(103 项共性加 3 项新增),覆盖医疗康养开放、电信、金融等,将政策底盘扩展至九个医院试点区域之外。
  • As of end-2025 a batch of wholly-foreign-owned hospitals had been approved, joining the 60-plus foreign-invested (mostly joint-venture) medical institutions already operating in China.
    截至 2025 年底,一批外商独资医院已获批,叠加中国已有的 60 余家外资(多为合资)医疗机构。
  • Practical constraints are real for foreign investors: TCM is excluded, public-hospital mergers are barred, and human-genetic-resource and data-export rules still apply — so JV and greenfield WFOE each carry trade-offs.
    外资办医仍有实质约束:不含中医类、不含并购公立医院,且人类遗传资源与数据出境规则仍适用——故合资或绿地独资各有权衡。

Foreign-invested hospitals: the 2026 liberalisation and where they can land | 2026 外资办医政策松绑与落地城市

Overview

Healthcare services are among the last major service sectors where foreign access remains conditional in China, but 2024–2026 has brought the most significant opening in a generation. The centrepiece is a pilot that, for the first time, permits wholly-foreign-owned hospitals in nine designated regions, alongside a long-standing joint-venture route that remains available nationwide. The 2026 “Stabilising and Improving Foreign Investment” action plan then commits to widening the pilot further.

This article traces the liberalisation timeline, the nine pilot regions and why they were chosen, the landing cases already on the ground, the joint-venture baseline, and the practical constraints and steps a foreign investor should plan around. It is informational guidance, not regulatory or legal advice.

The liberalisation timeline (2024–2026)

  • September 2024 — three-ministry medical pilot notice. The Ministry of Commerce, the National Health Commission (NHC) and the NMPA issued a notice opening pilot measures in healthcare. In biotech, foreign-invested enterprises were allowed, in the Beijing, Shanghai and Guangdong free-trade zones and the Hainan Free Trade Port, to conduct human stem-cell, gene-diagnosis and gene-therapy technology development and application for product registration and production. In the hospital field, the notice proposed allowing wholly-foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island (TCM excluded; no merger of public hospitals).
  • 1 November 2024 — negative list clears manufacturing. The 2024 negative list took effect, removing the last manufacturing-sector foreign-access restrictions. While hospitals are a service sector, this signalled the broader opening direction and eased ancillary manufacturing (e.g. devices, supplies) for foreign healthcare investors.
  • November 2024 — the WFOE-hospital pilot plan. The NHC, MOFCOM, the National Administration of Traditional Chinese Medicine and the China CDC published the *Pilot Work Plan for Expanding Opening in the Wholly-Foreign-Owned Hospital Field*, formalising the nine-region pilot and the exclusions.
  • January 2026 — nine-city services-opening pilot. MOFCOM issued the comprehensive services-opening pilot tasks for nine cities (led by Dalian), assigning 159 tasks — 103 common tasks plus 3 added — covering medical-senior-care opening, telecom, finance and more, broadening the policy floor well beyond the nine hospital-pilot regions.
  • June 2026 — action plan expansion signal. The State Council information office briefing on the “Stabilising and Improving Foreign Investment” action plan confirmed the biotech pilot covers the Beijing, Shanghai and Guangdong FTZs plus Hainan, and the wholly-foreign-owned-hospital pilot covers the nine regions; it committed to studying a further expansion of these pilot geographies after evaluating the initial rollout.

The nine pilot regions and why

The nine are Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island. The NHC’s stated rationale is practical. First, demand: these are high-openness, foreign-enterprise- and expatriate-dense locations with stronger multi-tiered healthcare demand. Second, governance maturity: since the 2000 *Interim Measures for Sino-Foreign Equity/Cooperative Medical Institutions*, a sizable share of Sino-foreign medical institutions have clustered in exactly these provinces, building regulatory experience. Third, investment weight: these regions account for over 45% of actual utilised foreign capital, making them natural magnets for hospital investment.

Landing cases already on the ground

  • Tianjin Pengruili Hospital — the flagship. On 16 December 2024 Tianjin issued the first wholly-foreign-owned tertiary general hospital licence; the hospital opened on 26 February 2025. Invested by Singapore’s Pengruili (Perennial) Group at about ¥1 billion with 500 beds, it offers broad specialties plus an international department for customised and chronic-disease management, and sits inside the Tianjin South Station health-city TOD complex.
  • Guangzhou — rehab and a tertiary general plan. A Guangzhou development zone partnership with Pengruili is building the city’s first wholly-foreign-owned specialty hospital (a rehabilitation hospital) expected to open by end-2026; a separate Baiyun district project (Phase-I ¥1 billion) is planned as South China’s first wholly-foreign-owned tertiary general hospital.
  • Hainan — timed to the FTP seal. On the day of the Hainan Free Trade Port’s “sealing” at end-2025, a Pengruili-invested wholly-foreign-owned rehabilitation hospital was established there.
  • Scale of the base. As of end-2025, a batch of wholly-foreign-owned hospitals had been approved, joining the 60-plus foreign-invested medical institutions (mostly joint ventures) already operating across China.

The joint-venture baseline (still nationwide)

Wholly-foreign-owned hospitals are a pilot privilege confined to nine regions. Outside them, foreign healthcare investment continues under the 2000 *Interim Measures*, which permit Sino-foreign equity or cooperative medical institutions subject to provincial/municipal health-commission approval. This JV route remains the workhorse for foreign groups that want a China footprint outside the pilot geographies, or that prefer a local partner for land, staffing and payer relationships. Many of the 60-plus existing foreign medical institutions are JVs, and they provide a proven template: foreign capital plus a Chinese partner navigating licensing, staffing and hospital-administration rules.

Practical constraints foreign investors must respect

The opening is real but bounded. Key guardrails:

  • TCM excluded. Wholly-foreign-owned hospitals may not be traditional Chinese-medicine institutions.
  • No public-hospital M&A. The pilot explicitly bars acquiring or merging public hospitals.
  • Human genetic resources. Hospitals engaging in research involving human genetic resources remain subject to HGR approval and compliance — a live constraint for internationally linked groups running trials or biobanks.
  • Data export and cybersecurity. Cross-border transfer of patient or research data must satisfy PIPL and cybersecurity/important-data rules; groups with regional or global data lakes need a compliant architecture.
  • Licensing and staffing. A 医疗机构执业许可证 from the competent health commission is mandatory, and foreign-trained physicians must meet PRC practice-qualification requirements.

What foreign investors should do next

  • Pick the structure by geography. Use the WFOE route only inside the nine pilot regions; elsewhere plan a JV under the 2000 measures.
  • Secure the licence early. Engage the provincial/municipal health commission on the 医疗机构执业许可证 pathway and timeline before committing capital.
  • Choose the city deliberately. Weight the nine pilot regions by expatriate demand, existing foreign-medical-institution experience, and real-estate/payer access; TOD health-city models (as Pengruili deployed) can de-risk fixed costs.
  • Model the exclusions. Confirm the project is neither TCM nor a public-hospital acquisition, and build HGR and data-export compliance into the design from day one.
  • Watch the 2026 expansion. Track the action plan’s further pilot-region enlargement — new eligible cities may open greenfield options without a JV.
  • Plan the JV alternative. Where speed or a local partner matters, the nationwide JV route remains available and battle-tested.

Common pitfalls

  • Assuming WFOE is allowed nationwide. It is confined to the nine pilot regions; elsewhere a JV is required.
  • Assuming TCM or public-hospital M&A is permitted. Both are explicitly excluded from the pilot.
  • Overlooking HGR and data-export rules. International groups running research or centralising data can breach HGR/PIPL without a compliant design.
  • Underestimating licensing and staffing lead times. The 执业许可证 and physician-qualification pathway are the critical path, not the capital.
  • Treating the pilot as settled national policy. It remains a pilot whose geography and conditions can expand or adjust — plan for change.

Sources

  • 国务院新闻办发布会介绍利用外资固稳促优有关政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 人民日报(海外版)《独资医院领域扩大开放试点工作方案》解读 (2024-12-03): https://paper.people.com.cn/rmrbhwb/pc/content/202412/03/content_30032517.html
  • 光明日报《我国首家外商独资三级综合医院开诊》(2025-02-27): https://m.gmw.cn/gmsogh/202502/27/37873333.html
  • 商务部(MOFCOM)官方门户:https://www.mofcom.gov.cn

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 外资办医政策松绑与落地城市

概述

医疗服务是中国少数外资准入仍属有条件开放的服务大类中之一,但 2024–2026 年迎来了 Generation 以来最显著的开放。核心是一项和以往不同、首次允许在九个指定区域设立外商独资医院的试点,同时全国仍可走的合资路线依旧有效。2026 年《利用外资固稳促优行动方案》进而承诺进一步扩大试点。

本文梳理开放时间线、九个试点区域及其选定逻辑、已落地的案例、合资基线,以及外资投资者须规划的实务约束与步骤。本文仅为信息参考,不构成监管或法律意见。

开放时间线(2024–2026)

  • 2024 年 9 月——三部委会医疗试点通知。 商务部、国家卫健委、国家药监局印发在医疗领域开展扩大开放试点的通知。生物技术领域,允许外商投资企业在北京、上海、广东自由贸易试验区与海南自由贸易港,从事人体干细胞、基因诊断与治疗技术开发和应用,用于产品注册上市和生产。医院领域,拟允许在北京、天津、上海、南京、苏州、福州、广州、深圳、海南全岛设立外商独资医院(中医类除外,不含并购公立医院)。
  • 2024 年 11 月 1 日——负面清单清空制造业。 2024 年版负面清单施行,清除制造业领域最后的外资准入限制。医院虽属服务业,但此举表明整体开放方向,并便利了外资医疗投资者的配套制造(如器械、耗材)。
  • 2024 年 11 月——独资医院试点方案。 国家卫健委、商务部、国家中医药局、国家疾控局公布《独资医院领域扩大开放试点工作方案》,固化九区域试点与除外情形。
  • 2026 年 1 月——九城市服务业扩大开放试点。 商务部印发大连等 9 城市服务业扩大开放综合试点任务,部署 159 项(103 项共性加 3 项新增),覆盖医疗康养开放、电信、金融等,将政策底盘大幅扩展至九个医院试点区域之外。
  • 2026 年 6 月——行动方案扩围信号。 国务院新闻办在《利用外资固稳促优行动方案》发布会上确认:生物技术试点覆盖北京、上海、广东 3 个自贸区加海南,外商独资医院试点覆盖九地;并承诺在评估初期落地后,抓紧研究进一步扩大上述领域试点地域范围。

九个试点区域及其逻辑

九地为北京、天津、上海、南京、苏州、福州、广州、深圳与海南全岛。国家卫健委给出的理由务实。其一,需求:这些地区开放度高、外资企业与外籍人员密集,多元化医疗需求更强。其二,治理成熟度:自 2000 年《中外合资、合作医疗机构管理暂行办法》以来,相当比例的中外医疗机构正聚集于这九省市,积累了监管经验。其三,投资权重:这些区域实际使用外资总额占比超 45%,天然是医院投资磁石。

已落地案例

  • 天津鹏瑞利医院——旗舰。 2024 年 12 月 16 日天津颁发首张外商独资三级综合医院执业许可证;医院于 2025 年 2 月 26 日开诊。由新加坡鹏瑞利集团投资约 10 亿元、设 500 张床位,提供多专科及面向定制与慢病管理的国际部,坐落于天津南站健康城 TOD 综合体。
  • 广州——康复与三级综合布局。 广州开发区与鹏瑞利合作建设全市首家外商独资专科医院(康复医院),预计 2026 年底运营;白云区另有一期投资 10 亿元的项目,规划为华南首家外商独资三级综合医院。
  • 海南——卡位封关。 2025 年底海南自由贸易港封关当日,鹏瑞利投资的外商独资康复医院同步落户。
  • 存量规模。 截至 2025 年底,一批外商独资医院已获批,叠加中国已有的 60 余家外资(多为合资)医疗机构。

合资基线(仍全国可用)

外商独资医院是限于九区域的试点特权。在其之外,外资办医仍依 2000 年《暂行办法》以中外合资或合作医疗机构形式,经省级/市级卫健部门批准设立。这条合资路线仍是想在中国落子、但位于试点区域之外,或偏好本地伙伴以处理土地、人员与支付关系的集团的主力选择。现有的 60 余家外资医疗机构多为合资,提供了成熟模板:外资加中国伙伴共同应对许可、人员与医院管理规则。

外资投资者须遵守的实务约束

开放真实但有边界。关键护栏:

  • 不含中医类。 外商独资医院不得为中医类机构。
  • 不含并购公立医院。 试点明确禁止并购或合并公立医院。
  • 人类遗传资源。 涉及人类遗传资源的研究仍须 HGR 审批与合规——对开展试验或生物样本库的国际化集团是实约束。
  • 数据出境与网络安全。 患者或研究数据的跨境传输须满足《个人信息保护法》及网络安全/重要数据规则;拥有区域或全球数据湖的集团需合规架构。
  • 许可与人员。 须取得卫健部门颁发的《医疗机构执业许可证》;境外 trained 医师须满足中国执业资格要求。

外资投资者下一步

  • 按地域选结构。 独资路线仅限九个试点区域内使用;区域外须按 2000 年办法走合资。
  • 尽早取证。 在投入资本前,就《医疗机构执业许可证》路径与时间表对接省级/市级卫健部门。
  • 审慎择城。 在九试点区域中按外籍需求、既有外资医疗经验、地产与支付可及性加权;TOD 健康城模式(如鹏瑞利)可摊薄固定成本。
  • 建模除外项。 确认项目既非中医类也非公立医院并购,并将 HGR 与数据出境合规从第一天纳入设计。
  • 跟踪 2026 年扩围。 关注行动方案进一步扩大的试点区域——新合格城市可能无需合资即开放绿地选项。
  • 规划合资备选。 当速度或本地伙伴重要时,全国可用的合资路线仍稳健可靠。

常见误读

  • 以为独资全国放开。 其限于九个试点区域;区域外须为合资。
  • 以为中医类或并购公立医院可行。 两者均被试点明确排除。
  • 忽视 HGR 与数据出境规��。 开展研究或集中数据的国际集团,若无合规设计易触 HGR/PIPL 红线。
  • 低估许可与人员周期。 执业许可证与医师资格路径才是关键路径,而非资本。
  • 把试点当既定国策。 其仍是试点,地域与条件可能扩围或调整——须为变化留预案。

来源

  • 国务院新闻办发布会介绍利用外资固稳促优有关政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 人民日报(海外版)《独资医院领域扩大开放试点工作方案》解读(2024-12-03):https://paper.people.com.cn/rmrbhwb/pc/content/202412/03/content_30032517.html
  • 光明日报《我国首家外商独资三级综合医院开诊》(2025-02-27):https://m.gmw.cn/gmsogh/202502/27/37873333.html
  • 商务部(MOFCOM)官方门户:https://www.mofcom.gov.cn

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan

Medical-device import registration and the foreign-device strategy under domestic substitution (2026)

  • Imported medical devices still require NMPA registration by risk class (I/II/III), and Class II/III overseas manufacturers must register their production sites with the NMPA before any China market entry.
    进口医疗器械仍须按风险分类(一/二/三类)取得国家药监局注册;二类、三类境外生产企业须向 NMPA 登记生产场地后方可进入中国。
  • Volume-Based Procurement has expanded from high-value implants into routine consumables: the coronary-stent renewal tender opened in Tianjin on 20 May 2026 with every bidder winning, and a 29-province electrosurgical-knife alliance VBP went live on 1 July 2026.
    集中带量采购已从高值植入物扩展到常规耗材:冠脉支架第二轮接续采购 2026 年 5 月 20 日在天津开标、投标企业全部中选;覆盖 29 省的电刀省际联盟集采于 2026 年 7 月 1 日落地。
  • Domestic substitution is measurably eroding foreign share — foreign penetration in some consumable segments fell from about 45% (2020) to under 25% (2025), and peripheral-vessel balloon localisation rose from 28% (2019) to roughly 58% (2025).
    国产替代正在实质侵蚀外资份额——部分耗材外资占比从约 45%(2020)降至 2025 年不足 25%,外周血管球囊国产化率从 28%(2019)升至 2025 年约 58%。
  • Foreign device makers are answering with in-China production: ERBE’s first locally built high-frequency surgical unit (VIO S CN) received its NMPA certificate on 11 June 2026 and rolled off the line on 1 July 2026.
    外资器械企业以”在华生产”应对:爱尔博首台国产高频手术设备 VIO S CN 于 2026 年 6 月 11 日获 NMPA 注册证,7 月 1 日下线。
  • VBP rules are shifting from “lowest-price-wins” toward value-based evaluation, rewarding firms with genuine technology, scale and supply stability rather than pure cost.
    集采规则正从”唯低价”转向综合价值评价,利好具备真实技术、规模与供应稳定性的企业。
  • The practical foreign-device strategy is to register imports to hold premium segments, localise production to defend volume segments under VBP, and engage the province alliances early.
    务实的外资器械策略是:以进口注册守住高端细分,以本地化生产捍卫集采下的走量细分,并尽早介入省际联盟。

Medical-device import registration and the foreign-device strategy under domestic substitution (2026) | 2026 医疗器械进口注册与国产替代下外资器械企业策略

Overview

Medical devices sit at the intersection of tight registration control and aggressive procurement reform. For a foreign device company, market access is a two-stage problem: first clear the NMPA registration gateway (still mandatory and class-based), then survive the commercial gateway of Volume-Based Procurement, where domestic substitution has become the explicit policy direction. 2026 is a pivotal year because VBP has pushed from headline implants — stents, joints — into everyday consumables, and because the 2024 negative-list “clearing” of manufacturing restrictions makes in-China production by a wholly foreign-owned plant straightforward for the first time.

This article explains the import-registration gateway, the 2026 VBP and substitution landscape, why localisation has become the default foreign response, and the practical moves a foreign device group should plan. It is informational guidance, not regulatory or legal advice.

The import-registration gateway

Registration is risk-tiered. Devices are classified Class I (low), Class II (medium) and Class III (high). Class I devices are filed with the provincial NMPA office; Class II and III require registration with the NMPA (via the Centre for Medical Device Evaluation, CMDE). A registration dossier needs product technical requirements, type testing at an accredited laboratory, and a clinical evaluation or trial unless the device falls under an exemption catalogue. Quality-system compliance (Good Manufacturing Practice for medical devices) is inspected, and — critically for importers — overseas manufacturers of Class II/III devices must register their production site with the NMPA.

A frequent blind spot is the clinical-evaluation route. Not every Class II/III device needs a trial: where a product is comparable to an already-marketed same-species device, a literature-and-data “same-species” comparison can support trial exemption; novel or high-risk devices with no predicate still require a trial. The route choice dictates evidence cost and launch pace and should be settled at project kick-off. Imported products also need Chinese labels and package inserts; customs clearance hinges on the NMPA registration certificate as a key document.

The 2026 VBP and substitution landscape

VBP — the “集中带量采购” program that exchanges steep price cuts for committed volume — has become the dominant commercial gate for devices, and 2026 shows it reaching deeper into consumables.

Coronary stents, renewal round. On 20 May 2026 the national organisation opened the second renewal tender for coronary stents in Tianjin. Fifteen enterprises with 30 products bid, all bidders won, and 27 products were pre-selected — including upgraded new products from both foreign players (Medtronic’s “Resolute Onyx”, Abbott, Boston Scientific) and domestic leaders (MicroPort, Lepu, JW). Demand came from 4,468 medical institutions (up 86% vs the first tender) with an annual requirement of about 2.73 million stents (up 155%). Stainless-steel stents were included in the national tender for the first time at a ceiling of ¥848, while the alloy-stent ceiling was raised about 11.9% to ¥949 — a signal that rules are moderating toward value rather than pure price.

Electrosurgical knives, 29-province alliance. A Hunan-led inter-provincial alliance covering 29 provinces, municipalities and the Xinjiang Production and Construction Corps went live on 1 July 2026, with a two-year purchasing cycle and total volume above 20 million units/pieces and a market scale above ¥3.5 billion. In 17 core bidding groups, domestic brands took the lowest bid in 16 — and analysts estimate foreign share of the electrosurgical consumable market (above 50% before the tender) could fall below 30% afterward.

Broader alliance activity. The “3+N” and provincial alliances kept broadening through 2026: dural patches and indwelling needles (Tianjin-led, results published 11 March 2026), digestive-intervention snares, peripheral-vessel balloons and orthopaedic irrigation systems (Hebei-led product briefings in March 2026), plus起搏器 and peripheral micro-catheters spanning 27–29 provinces. The clear trend: VBP is becoming the normal commercial environment across the device catalogue.

Measurable substitution. The effect on foreign share is concrete. In digestive-intervention snares, foreign brands’ share fell from about 45% (2020) to under 25% (2025) as domestic players like Micro-Tech pushed hospital penetration above 70%. In peripheral-vessel constrained balloons — long monopolised by Medtronic and Abbott — localisation rose from 28% (2019) to about 58% (2025) and is expected to exceed 70% after the latest tender, with domestic leaders Lepu, Volcano (Huatai) and HeartCare (MicroPort) capturing share. Foreign brands retain an edge only in complex, high-end niches where price gaps of 3–5× still apply but where VBP’s volume logic steadily erodes the addressable market.

Why localisation is now the default response

Faced with VBP price compression and substitution pressure, an increasing number of foreign device makers are shifting from “import the finished unit” to “build it in China.” The logic is operational as much as commercial.

ERBE’s VIO S CN is the 2026 template. ERBE, the German electrosurgery leader (market share ~43.9% of high-frequency surgical-equipment tenders in Jan–May 2026), had imported its units from Germany, absorbing long shipping and customs lead times and high distribution cost. Its first China-built host, VIO S CN — developed with deep Chinese-team input on the German production system — received its NMPA registration certificate on 11 June 2026 and rolled off the line on 1 July 2026. Local production compresses logistics and import cost and sharply improves supply responsiveness, exactly the variables VBP punishes importers on.

Manufacturing is now open. The 2024 negative list cleared all manufacturing-sector foreign-access restrictions (effective 1 November 2024), so a wholly foreign-owned device manufacturing plant in China no longer faces the sector caps that once applied. Combined with theNMPA production-site registration for Class II/III, a foreign maker can stand up a China plant, register the site, and obtain domestic NMPA certificates for locally made SKUs — converting an “import” into a “domestic product” for tender purposes.

The rules now reward local players’ strengths. VBP design is moving from pure price toward comprehensive value evaluation — technical briefing, clinical argument, cost verification — which preserves reasonable margin for firms with real technology and scale. Local production is the most direct way for a foreign maker to match domestic competitors on price, lead time and supply stability while keeping original-equipment quality.

2026 policy context

  • Innovation prioritisation. The Medical Device Supervision and Administration Regulation directs that innovative devices receive priority review and approval, supporting domestic and foreign innovators alike in bringing novel products to market.
  • Manufacturing fully open. The 2024 negative list’s removal of the last manufacturing restrictions means device manufacturing welcomes wholly foreign-owned investment nationwide.
  • Opening under the 2026 action plan. The “Stabilising and Improving Foreign Investment” action plan (effective 1 July 2026) reinforces a pro-foreign-investment stance across healthcare and supports measures such as drug segmented manufacturing and expanded biotech/hospital pilots — the broader policy backdrop foreign device groups operate within.

What foreign device groups should do next

  • Map the portfolio against VBP exposure. Classify each SKU by whether it sits in a tendered category, its substitution risk, and whether it is premium/non-substitutable or volume/price-sensitive.
  • Keep importing where defensible. For high-end, clinically differentiated devices with weak domestic predicates, hold the import-registration route and protect premium positioning.
  • Localise where volume is at stake. For tendered, price-sensitive lines, stand up or contract China manufacturing, register the site with the NMPA, and obtain domestic certificates to compete on VBP terms.
  • Settle the clinical-evaluation route early. Decide same-species comparison, exemption or full trial at kick-off to fix evidence cost and timeline.
  • Engage the alliances proactively. Track province-alliance pipelines (Hebei, Tianjin “3+N”, Hunan, Guangdong, Zhejiang) and prepare technical briefings that support value-based evaluation.
  • Prepare Chinese labelling, inserts and a traceability system before launch, and treat the NMPA registration certificate as the customs-critical document.

Common pitfalls

  • Assuming registration equals access. Clearing NMPA registration is necessary but not sufficient; VBP outcome, not the certificate, often decides volume.
  • Importing into a tendered category. Finished-unit imports cannot match localised competitors on VBP price and lead time and will lose share.
  • Ignoring the production-site registration. Class II/III overseas manufacturers must register their site with the NMPA — a step easily missed when planning local production.
  • Treating VBP as pure price. Rules now weight technology and supply stability; a weak value story loses even when price is competitive.
  • Late alliance engagement. By the time a tender opens, grouping and evaluation are largely set; influencing them requires early technical briefing.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • 国家医疗保障局(NHSA)——集中带量采购:https://www.nhsa.gov.cn/
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 国务院《利用外资固稳促优行动方案》(2026-06): https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 医疗器械进口注册与国产替代下外资器械企业策略

概述

医疗器械处在严格注册控制与激进采购改革的十字路口。对外资器械企业而言,市场准入是两段式问题:先越过国家药监局的注册关口(仍属强制且按类管理),再穿越集中带量采购这一商业关口——而国产替代已是明确的政策方向。2026 年是关键之年:集采从支架、关节等标志性植入物,推进到日常耗材;同时 2024 年版负面清单”清零”制造业准入限制,使外商独资器械工厂在华设厂首次变得顺理成章。

本文说明进口注册关口、2026 年集采与替代格局、为何本土化已成为外资的默认应对,以及外资器械集团应规划的务实举措。本文仅为信息参考,不构成监管或法律意见。

进口注册关口

注册按风险分类管理。器械分为第一类(低)、第二类(中)、第三类(高)。第一类向省级药监部门备案;第二类、第三类须向国家药监局(经医疗器械技术审评中心 CMDE)注册。注册资料需产品技术要求、资质实验室型检,以及临床评价或临床试验(除非属豁免目录)。质量体系(《医疗器械生产质量管理规范》)须受检,且——对进口商关键的是——二类、三类境外生产企业须向国家药监局登记其生产场地。

常见盲点是临床评价路径。并非所有二类、三类器械都需临床试验:若产品与已上市同品种器械可比,可通过文献与数据的”同品种”比对支持免于临床;无同品种可比或高风险的创新器械仍须开展临床试验。该路径选择决定证据成本与上市节奏,应在立项时即敲定。进口产品还须配中文标签与说明书;清关以国家药监局注册证为关键单证。

2026 年集采与替代格局

集中带量采购(”集采”以大幅降价换取约定采购量)已成为器械主导性商业关口,而 2026 年显示其正深入日常耗材。

冠脉支架,接续轮。 2026 年 5 月 20 日,国家组织在天津开标冠脉支架第二轮接续采购。15 家企业、30 个产品投标,投标企业全部中选,27 个产品获拟中选资格——既含外资新品(美敦力”Resolute Onyx”、雅培、波士顿科学),也含国内龙头(微创、乐普、吉威)。填报需求来自 4468 家医疗机构(较首轮增 86%),年度需求量约 273 万个(增 155%)。不锈钢支架首次纳入国家集采,最高有效申报价 848 元;合金支架上限由 848 元上调约 11.9% 至 949 元——信号是规则正从唯价向价值适度回调。

电刀,29 省联盟。 湖南牵头的省际联盟覆盖 29 个省区市及新疆生产建设兵团,于 2026 年 7 月 1 日落地,采购周期两年,总需求量超 2000 万把/片,市场规模超 35 亿元。17 个核心竞价组中,国产品牌包揽 16 组最低报价;分析估计外资电外科耗材份额(集采前超 50%)此后或降至 30% 以下。

更广的联盟活动。 “3+N”与省级联盟在 2026 年持续扩围:硬脑(脊)膜补片与留置针(天津牵头,3 月 11 日公布结果)、消化介入圈套器、外周血管约束型球囊与骨科冲洗系统(河北 3 月产品介绍)、以及覆盖 27–29 省的起搏器与外周微导管。清晰趋势:集采正成为器械目录的常态化商业环境。

可量化的替代。 对外资份额的影响很具体。消化介入圈套器领域,外资占比从约 45%(2020)降至 2025 年不足 25%,南微医学等国产将二级以上医院渗透率推过 70%。外周血管约束型球囊——长期由美敦力、雅培垄断——国产化率从 28%(2019)升至 2025 年约 58%,最新集采后有望破 70%,国产龙头乐普、惠泰、心脉抢占份额。外资仅在复杂高端细分仍具优势,但集采的量价逻辑持续压缩其可及市场。

为何本土化成为默认应对

面对集采降价与替代压力,越来越多外资器械企业正从”进口整机”转向”在华制造”。其逻辑既是商业也是运营。

爱尔博 VIO S CN 是 2026 年范本。 德国电外科龙头爱尔博(2026 年 1–5 月高频手术设备中标市占约 43.9%)此前整机自德国进口,承受漫长海运、跨境报关的高流通成本与长供货周期。其首台国产主机 VIO S CN——由中国团队深度参与、依托德国原装生产体系——于 2026 年 6 月 11 日获国家药监局注册证,7 月 1 日下线。本地生产压缩物流与进口成本,并显著提升供货响应,而这正是集采惩罚进口商的变量。

制造业现已放开。 2024 年版负面清单清空了制造业领域外资准入限制(2024 年 11 月 1 日施行),外商独资器械制造厂在华不再面临此前的行业上限。结合二类、三类器械的 NMPA 生产场地登记,外资可在中国建厂、登记场地,并为本地生产单品取得国产注册证——将”进口”转为集采意义上的”国产”。

规则现在奖励本地玩家的强项。 集采设计正从纯价格转向综合价值评价——技术介绍、临床论证、成本核验——为具备真实技术与规模的企业保留合理利润。本地生产是外资在价格、交期与供应稳定性上对标国产、同时保留原厂品质的最直接方式。

2026 年政策语境

  • 创新优先。 《医疗器械监督管理条例》明确支持创新医疗器械优先审评审批,惠及本土与外资创新者将新产品推向市场。
  • 制造业全面放开。 2024 年负面清单清除最后制造业限制,意味着器械制造在全国欢迎外商独资投资。
  • 行动方案下的开放。 《利用外资固稳促优行动方案》(2026 年 7 月 1 日落地)重申亲外资立场,并支持药品分段生产、扩大生物技术与人独资医院试点等举措——这是外资器械企业所处的更宽政策背景。

外资器械集团下一步

  • 按集采敞口映射产品组合。 将每个单品归类至是否属集采品类、替代风险高低、以及是溢价不可替还是走量价格敏感。
  • 在可守处继续进口。 对临床差异化强、国产无同品种可比的高端器械,守住进口注册路线并保护溢价定位。
  • 在走量处本土化。 对集采、价格敏感产线,自建或合同制造,向国家药监局登记场地并取得国产证,以集采条款竞争。
  • 尽早敲定临床评价路径。 立项即决定同品种比对、免于临床或临床试验,以固定证据成本与时间表。
  • 主动介入联盟。 跟踪河北、天津”3+N”、湖南、广东、浙江等省际联盟动向,准备支撑价值评价的技术介绍。
  • 上市前备好中文标签、说明书与可追溯体系,并将国家药监局注册证视为清关关键单证。

常见误读

  • 以为注册即准入。 越过国家药监局注册是必要非充分;决定销量的常是集采结果而非证书。
  • 把整机进口进集采品类。 进口整机在集采价格与交期上无法对标本土化对手,必失份额。
  • 忽视生产场地登记。 二类、三类境外生产企业须向国家药监局登记场地——规划本地生产时极易遗漏。
  • 把集采当纯价格。 规则现已权衡技术与供应稳定性;价值陈述薄弱者即便价格有竞争力也会落败。
  • 联盟介入太晚。 集采开标时分组与评价基本已定;影响它们需提前技术介绍。

来源

  • 国家药品监督管理局(NMPA)——官方门户:https://www.nmpa.gov.cn
  • 国家医疗保障局(NHSA)——集中带量采购:https://www.nhsa.gov.cn/
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 国务院《利用外资固稳促优行动方案》(2026-06):https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan

China’s innovative-drug market and the foreign-pharma China playbook (2026)

  • China’s innovative-drug market is projected to exceed ¥1.3 trillion in 2026, with 2025 out-licensing deals reaching roughly US$135 billion and the first quarter of 2026 alone surpassing US$60 billion.
    2026 年中国创新药市场规模预计突破 1.3 万亿元;2025 年对外授权交易总额约 1357 亿美元,2026 年一季度即突破 600 亿美元。
  • The 2026 Government Work Report named biopharmaceuticals an “emerging pillar industry” for the first time, and a revised drug-administration regulation effective 15 May 2026 introduces six-year data protection and seven-year rare-disease exclusivity.
    2026 年政府工作报告首次将生物医药列为”新兴支柱产业”;2026 年 5 月 15 日施行的药品管理新规引入 6 年数据保护与 7 年罕见病市场独占。
  • Foreign pharma’s China role has shifted from “sell-in” to “license-in and co-develop”: multinationals now source early-stage assets from Chinese biotechs at an estimated 30%–40% of US development cost.
    外资药企在华角色已从”卖药”转向”引进与共创”:跨国药企以约为美国 30%–40% 的成本从中国 Biotech 采购早期管线。
  • AstraZeneca, Novartis, Roche, Sanofi and Lilly have announced deep localisation commitments — AstraZeneca alone plans over ¥100 billion by 2030 in China R&D and manufacturing.
    阿斯利康、诺华、罗氏、赛诺菲、礼来等已宣布深度本土化承诺——仅阿斯利康便计划 2030 年前在华投入超 1000 亿元用于研发与制造。
  • NMPA’s ICH alignment and priority-review pathways let China-discovered assets reach global markets faster, recasting China as an innovation “source” rather than only a “market.”
    国家药监局与 ICH 接轨及优先审评通道,使中国发现的资产更快走向全球,将中国从单纯的”市场”重塑为创新”源头”。
  • Practical entry levers for foreign players are license-in partnerships, local R&D centres, in-China manufacturing, and active NRDL/VBP engagement — not import-only models.
    外资企业的务实抓手是授权引进合作、本土研发中心、在华生产,以及主动参与医保目录/集采,而非单纯进口模式。

China’s innovative-drug market and the foreign-pharma China playbook (2026) | 2026 中国创新药市场与外资药企的中国策略

Overview

China’s innovative-drug sector has moved from “imitation-driven” to “innovation-exporting” in a matter of years, and 2026 is the year that shift became structural. The macroeconomic framing is unusually explicit: the 2026 Government Work Report named biopharmaceuticals an “emerging pillar industry” for the first time, placing the sector alongside integrated circuits, aerospace and the low-altitude economy. For foreign-invested pharmaceutical companies, the implication is that China is no longer just a sales territory to be supplied from overseas plants — it is now a discovery and development engine that multinationals are increasingly woven into.

This article maps the 2026 market size and deal landscape, explains why foreign pharma is “going Chinese” through license-in and co-development, details the localisation playbook foreign groups are deploying, and sets out practical entry levers. It is informational guidance, not regulatory or legal advice; confirm current rules with the NMPA and qualified PRC counsel.

Market context: scale, output and the BD boom

The market is large and still expanding. Industry estimates put China’s innovative-drug market at about ¥1.13 trillion in 2024, roughly ¥1.22 trillion in 2025, and a projected ¥1.3 trillion-plus in 2026. The growth story is less about volume than about structure: domestic innovative assets now dominate new approvals. The NMPA approved 76 innovative drugs in 2025 — up about 58% year-on-year, with domestically developed products accounting for more than 80% of the total. By mid-April 2026 the regulator had already cleared 13 innovative drugs for the year, including six first-in-class medicines, and by the end of the first quarter it had approved 10, eight of them domestic.

The pipeline is globally significant. At the end of 2025 China had 4,751 drugs in active research, about 33.7% of the global total — making it the largest single-country pipeline in the world. In next-generation modalities the lead is sharper still: as of late 2025 China contributed roughly 34% of early-stage next-generation-therapy pipelines globally, and led in antibody-drug conjugates (ADCs, ~54% share) and bispecific/multispecific antibodies (~48% share).

The defining commercial event of 2025–2026 is the outbound-licensing (BD) surge. Chinese drugmakers signed more than 150 out-licensing agreements in 2025 with total deal value above US$135 billion — the first time China surpassed the United States as the top source of such deals globally. The momentum accelerated into 2026: NMPA preliminary statistics show out-licensing deal value exceeded US$60 billion in the first three months of 2026, already nearly half of the prior full year’s total, and one industry tracker put Q1 2026 cross-border out-licensing at about US$61.4 billion, roughly 70% of global deal value that quarter. Deal structure is also evolving from single-asset licensing toward broader platform partnerships and NewCo structures that retain long-term upside for the Chinese originator.

Why foreign pharma is “going Chinese”

For most of the 2010s, a multinational’s China operation meant importing finished products and running local sales. That model is being replaced by deep integration into China’s discovery ecosystem. Three forces drive the change.

Cost-and-quality arbitrage. Bankers close to the market note that, for early-stage innovative assets, multinational “China sourcing” can cost an estimated 30%–40% of the equivalent US development cost while matching or beating efficacy — a combination that makes China a core pipeline source rather than a peripheral one. A senior JPMorgan healthcare banker has cited a multinational CFO’s view that, where the same pipeline can be sourced in China at a fraction of US cost with potentially superior outcomes, the choice is obvious.

A maturing, globally credible asset base. China’s regulatory system has converged with international standards: by the end of 2025 the NMPA had issued 71 ICH implementation announcements covering the full arc from early research to manufacturing quality control. Clinical-trial data generated in China under ICH-GCP now have a credible pathway to acceptance by the US FDA and EU EMA for global filings. China registered 5,173 drug trials in 2025, up nearly 99% from 2,602 in 2020, and patient recruitment cycles run shorter than the global average — a real operating-efficiency advantage for global programs.

Confidence expressed in cash. The headline license deals of 2025–2026 read like a roll-call of China-to-world transactions: CSPC signed a multi-project peptide partnership with AstraZeneca in January 2026; Sino Biopharm out-licensed a JAK/ROCK inhibitor to Sanofi for US$1.53 billion; Innovent extended its long-running Lilly alliance with a deal carrying US$350 million upfront and up to ~US$8.5 billion in milestones; and 3SBio’s PD-1/VEGF bispecific drew a record US$1.25 billion upfront from Pfizer. These are not one-off asset sales — they signal a structural re-rating of Chinese innovation as a global supply source.

The localisation playbook foreign groups are deploying

Foreign pharma is backing this strategic shift with capital and bricks. The pattern has moved from “light-asset sales offices” to “heavy-asset rooted platforms.”

R&D centres with real decision rights. AstraZeneca opened its sixth global strategic R&D centre in Beijing in October 2025 (a US$2.5 billion investment) and runs a parallel Shanghai engine; it plans to exceed ¥100 billion (about US$15 billion) of cumulative China R&D and manufacturing investment by 2030, including cell-therapy and radioligand-therapy bases in Shanghai and Guangzhou. Roche’s Shanghai innovation centre holds independent new-drug decision authority, with more than ten locally discovered molecules advanced to clinic, and its China Accelerator (launched 2021) had brought nearly 20 domestic biotech startups into its orbit by end-2024. Novartis operates three China R&D sites (Shanghai, Beijing, Suzhou) and, since 2024, has struck potential cooperation worth over ¥80 billion with Chinese innovators across cardiovascular, oncology, renal and neuroscience. Pfizer’s Beijing R&D centre, its third in China, anchors a “China-All-In” strategy embedding China in global early and pivotal Phase III programs.

Manufacturing upgraded to high-value categories. Sanofi broke ground on a Beijing insulin active-pharmaceutical-ingredient project (€1 billion) in October 2025 and opened a Chengdu innovation-and-operations centre in March 2026 (12,600 m², ~600 jobs). Lilly plans US$3 billion of China investment over the decade, including a US$200 million Suzhou expansion and Beijing/Shanghai incubators. Roche is building a Zhangjiang biopharma base (¥2.04 billion) and a Suzhou diagnostics plant (its largest single China investment). Novo Nordisk’s Tianjin site has drawn cumulative investment above ¥10 billion, with a further ¥4 billion quality-lab expansion completing in 2026.

Ecosystem co-creation over wholly-owned control. The dominant new mode is “capital + technology + ecosystem”: J&J’s JLABS Shanghai is among its largest global incubators; Bayer’s Zhangjiang co-creation platform targets small molecules, nucleic-acid drugs and AI drug discovery; AstraZeneca and CICC run a healthcare fund; and NewCo structures let Chinese originators retain upside while importing global capital and management. The logic, in one executive’s phrasing, is to “monetise current value while embedding into the global innovation network.”

2026 policy tailwinds

Beyond market pull, the policy environment in 2026 actively supports foreign participation.

  • Emerging-pillar status. The 2026 Government Work Report’s explicit naming of biopharmaceuticals as a pillar industry signals sustained, cross-ministry support rather than a one-off stimulant.
  • Stronger IP and exclusivity. A revised regulation implementing the Drug Administration Law took effect on 15 May 2026, introducing six-year regulatory data protection, seven-year market exclusivity for rare-disease drugs, and additional incentives for paediatric medicines — measures analysts say improve China’s attractiveness for global development partnerships.
  • Faster access. New-drug clinical-trial review timelines have been compressed from 60 to 30 working days, and time from approval to NRDL inclusion has shortened to about one year, narrowing the commercialisation gap that previously discouraged multinationals from launching novel assets in China first.
  • Openness under the 2026 action plan. The “Stabilising and Improving Foreign Investment” action plan (effective 1 July 2026) supports drug segmented-manufacturing rules and expands biotech and wholly-foreign-owned-hospital pilot regions — see the companion brief on pharma opening measures — reinforcing the message that foreign players are welcome across the value chain.

What foreign players should do next

  • Reframe China as a source, not just a market. Build or buy access to Chinese discovery assets through license-in, platform partnerships and NewCo structures rather than relying solely on imported products.
  • Plant R&D and manufacturing roots. Where the portfolio justifies it, establish or expand in-China R&D centres with local decision rights and high-value local manufacturing — this is now the expectation, not the exception.
  • Engage the NRDL/VBP reality early. Reimbursement and volume-based procurement determine commercial viability for most drugs; model them as part of the entry case, not as downstream marketing.
  • Leverage the regulatory convergence. Use ICH-aligned, China-generated data for global filings and consider China for simultaneous global trials to exploit speed and recruitment efficiency.
  • Protect the downside. Pair deeper integration with robust IP, data-protection and compliance posture, given the higher capital commitment localisation entails.

Common pitfalls

  • Treating China as a sales outpost. Groups that import only will miss the cost and speed advantages of Chinese discovery and risk being out-competed by locals and by peers who localised earlier.
  • Assuming overseas approval substitutes for China registration. An FDA/EMA licence does not register a product in China; a separate NMPA pathway with Chinese data is still required.
  • Under-resourcing local decision rights. Centres without real pipeline authority become expensive liaison offices; the winners grant China teams genuine development mandates.
  • Ignoring reimbursement until launch. NRDL and VBP outcomes — not the registration grant — often decide commercial success.
  • Over-concentrating in one modality. China’s strength is broad (ADC, bispecifics, GLP-1, cell therapy, radioligand), so a single-theme bet underuses the ecosystem.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • NMPA — English portal: https://english.nmpa.gov.cn
  • 国务院《利用外资固稳促优行动方案》(2026-06, 商资发〔2026〕97号): https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 中国创新药市场与外资药企的中国策略

概述

中国创新药产业在数年间完成了从”仿创结合”到”创新输出”的跃迁,而 2026 年正是这一转变固化为结构性的时点。宏观层面的定调尤为罕见:2026 年政府工作报告首次将生物医药列为”新兴支柱产业”,与集成电路、航空航天、低空经济并列。对在华外资药企而言,这意味着中国已不再只是由海外工厂供货的销售疆域,而是跨国药企日益深度嵌入的发现与开发引擎。

本文梳理 2026 年的市场规模与交易格局,解释外资药企为何通过授权引进与共创走向”中国化”,剖析外资集团正在部署的本土化打法,并给出务实的进入抓手。本文仅为信息参考,不构成监管或法律意见;请以国家药监局及合格中国法律顾问确认最新规则。

市场语境:规模、产出与 BD 热潮

市场体量庞大且仍在扩张。行业估算显示,2024 年中国创新药市场规模约 1.13 万亿元,2025 年约 1.22 万亿元,2026 年预计突破 1.3 万亿元。增长故事的关键在于结构而非规模:国产创新资产如今主导新获批品种。国家药监局 2025 年批准 76 款创新药,同比增长约 58%,其中国产占比超过 80%。截至 2026 年 4 月中旬,监管方年内已放行 13 款创新药,含 6 款首创新药;到一季度末已批 10 款,其中 8 款为国产。

研发管线具备全球分量。2025 年底,中国在研创新药达 4751 个,约占全球总量的 33.7%,是全球单一国家中最大的在研管线。在下一代疗法领域领先更明显:截至 2025 年三季度,中国贡献了全球早期下一代疗法管线的约 34%,并在抗体偶联药物(ADC,约 54% 份额)与双抗/三抗(约 48% 份额)领域领跑。

2025–2026 年最具标志性的商业事件是出海授权的爆发。2025 年中国药企签署对外授权协议超 150 笔,总交易额逾 1357 亿美元,首次超越美国成为全球第一来源地。势头在 2026 年加速:国家药监局初步统计显示,2026 年前三个月对外授权交易额突破 600 亿美元,已接近上年全年的半数;有行业跟踪机构测算一季度跨境对外授权约 614 亿美元,约占当季全球交易额的 70%。交易结构也正从单资产授权,演进为更广泛的平台合作与保留长期上行空间的 NewCo 模式。

外资药企为何”中国化”

在 2010 年代的大部分时间里,跨国药企的中国业务意味着进口成品加本地销售。这一模式正被深度融入中国发现生态所取代,背后有三股力量。

成本与质量的套利。 贴近市场的投行人士指出,对早期创新资产而言,跨国药企的”中国采购”成本可低至美国开发成本的 30%–40%,且疗效相当或更优——这一组合使中国从边缘来源变为核心管线来源。某资深摩根大通医疗健康银行家援引一家跨国药企 CFO 的观点:当同一管线能以美国几分之一的成本在华获取且可能疗效更优时,选择不言自明。

成熟且全球可信的资产基础。 中国监管体系已与国际接轨:截至 2025 年底,国家药监局已发布 71 项 ICH 实施公告,覆盖从早期研究到生产质量控制的完整链条。按 ICH-GCP 在中国生成的数据,已具备被美国 FDA、欧洲 EMA 接受并用于全球申报的可行路径。2025 年中国登记药物临床试验 5173 项,较 2020 年的 2602 项增长近 99%,且患者入组周期短于全球平均——这对全球研发项目是真实的运营效率优势。

以资金表达的信心。 2025–2026 年的重磅授权交易堪称中国走向世界的清单:2026 年 1 月石药与阿斯利康签署多肽多项目合作;中国生物制药以 15.3 亿美元将 JAK/ROCK 抑制剂授权给赛诺菲;信达延展与礼来的长期联盟,交易含 3.5 亿美元首付款及最高约 85 亿美元里程碑;三生制药 PD-1/VEGF 双抗更从辉瑞处拿下 12.5 亿美元创纪录首付款。这些不是一次性资产出售,而是对中国创新作为全球供给源的系统性重估。

外资集团正在部署的本土化打法

外资药企正以资本与实体落地为这一战略转向背书。路径已从”轻资产销售办公室”升级为”重资产扎根平台”。

拥有真实决策权的研发中心。 阿斯利康 2025 年 10 月启用北京全球战略研发中心(25 亿美元投资),并与上海引擎并列;计划 2030 年前在华研发与制造累计投入超 1000 亿元,含上海细胞治疗与广州放射偶联药物基地。罗氏上海创新中心拥有独立新药决策权,已有十余款本土发现分子推进至临床;其 2021 年启动的中国加速器截至 2024 年底已引入近 20 家本土 Biotech。诺华在华运营上海、北京、苏州三处研发站点,且自 2024 年以来与本土创新者的潜在合作规模超 800 亿元,覆盖心血管、肿瘤、肾脏与神经科学。辉瑞北京研发中心作为其中国第三家研发中心,承载将中国纳入全球早期与关键三期同步开发的”China-All-In”战略。

向高价值品类升级的制造。 赛诺菲 2025 年 10 月在京启动胰岛素原料药项目(10 亿欧元),并于 2026 年 3 月启用成都创新与运营中心(1.26 万平方米、约 600 个岗位)。礼来计划十年内在华投资 30 亿美元,含 2 亿美元苏州扩建及北京/上海孵化器。罗氏正建设张江生物制药基地(20.4 亿元)与苏州诊断工厂(其在华最大单笔投资)。诺和诺德天津基地累计投资已超百亿元,并追加 40 亿元质量实验室扩建于 2026 年完工。

以生态共创取代全资控制。 主流新模式是”资本+技术+生态”:强生 JLABS 上海是其全球规模最大的孵化器之一;拜耳张江共创平台聚焦小分子、核酸药物与 AI 药物发现;阿斯利康与中金设立医疗健康基金;NewCo 结构让中国原创方保留上行空间,同时引入全球资本与管理。用一位高管的话说,其逻辑是”在兑现当期价值的同时,嵌入全球创新网络”。

2026 年政策顺风

除市场拉力外,2026 年的政策环境主动支持外资参与。

  • 支柱地位。 2026 年政府工作报告明确将生物医药列为支柱产业,意味着跨部委的持续支持,而非一次性刺激。
  • 更强 IP 与独占期。 落实《药品管理法》的修订条例于 2026 年 5 月 15 日施行,引入 6 年数据保护、7 年罕见病市场独占及儿科用药额外激励——分析人士认为这提升了中国对全球开发合作的吸引力。
  • 更快可及。 新药临床试验审评时限已从 60 个工作日压缩至 30 个,从获批到纳入医保目录的时间缩短至约一年,收窄了此前阻碍跨国药企在华首发新品的商业化落差。
  • 行动方案下的开放。 《利用外资固稳促优行动方案》(2026 年 7 月 1 日落地)支持药品分段生产细则并扩大生物技术、外商独资医院试点区域——详见姊妹篇《医药产业开放新措施》——强化外资可全程参与价值链的信号。

外资企业应做的下一步

  • 将中国重构为源头而非仅市场。 通过授权引进、平台合作与 NewCo 结构建立或买断对中国发现资产的触达,而非仅依赖进口产品。
  • 植下研发与制造的树根。 若组合justify,应设立或扩地在华研发中心并赋予本地决策权,并布局高价值本地制造——这已成为预期,而非例外。
  • 早介入医保/集采现实。 报销与带量采购决定多数药品的商业可行性,应作为进入论证的一部分,而非下游营销问题。
  • 借力监管接轨。 用 ICH 接轨、中国生成的数据支撑全球申报,并考虑以中国承接全球同步试验,以利用速度与入组效率。
  • 守住下行。 因本土化意味着更高资本承诺,须配套稳健的 IP、数据保护与合规体系。

常见误读

  • 把中国当销售前哨。 仅做进口的企业将错失中国发现的成本与速度优势,并被本土企业及更早本土化的同行反超。
  • 以为境外批准可替代中国注册。 FDA/EMA 许可不等于在中国注册;仍需走完国家药监局的独立路径并常需中国数据。
  • 本地决策权投入不足。 没有真实管线权限的中心沦为昂贵联络处;赢家授予中国团队真正的开发授权。
  • 上市前才想报销。 决定商业成败的常是医保目录与集采结果,而非注册批件。
  • 单一赛道过度集中。 中国优势面广(ADC、双抗、GLP-1、细胞治疗、放射配体),单主题下注浪费了生态。

来源

  • 国家药品监督管理局(NMPA)——官方门户:https://www.nmpa.gov.cn
  • NMPA——英文门户:https://english.nmpa.gov.cn
  • 国务院《利用外资固稳促优行动方案》(2026-06,商资发〔2026〕97号):https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan